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Abstract
This international multidisciplinary document intends to provide clini-
cians with evidence-based practical patient-centered recommenda-
tions for evaluating patients and decedents with (aborted) sudden
cardiac arrest and their families. The document includes a framework
for the investigation of the family allowing steps to be taken, should
an inherited condition be found, to minimize further events in
affected relatives. Integral to the process is counseling of the patients
and families, not only because of the emotionally charged subject, but
because finding (or not finding) the cause of the arrest may influence
management of family members. The formation of multidisciplinary
teams is essential to provide a complete service to the patients and
their families, and the varied expertise of the writing committee
was formulated to reflect this need. The document sections were
divided up and drafted by the writing committee members according
to their expertise. The recommendations represent the consensus
opinion of the entire writing committee, graded by Class of Recom-
mendation and Level of Evidence. The recommendations were opened
for public comment and reviewed by the relevant scientific and clinical
document committees of the Asia Pacific Heart Rhythm Society
(APHRS) and the Heart Rhythm Society (HRS); the document under-
went external review and endorsement by the partner and collabo-
rating societies. While the recommendations are for optimal care, it
is recognized that not all resources will be available to all clinicians.
Nevertheless, this document articulates the evaluation that the clini-
cian should aspire to provide for patients with sudden cardiac arrest,
decedents with sudden unexplained death, and their families.
KEYWORDS Brugada syndrome; Cardiac arrest; Cardiac genetics; Catechol-
aminergic polymorphic ventricular tachycardia; Defibrillator; Expert
consensus statement; Genetic counseling; Guidelines; Long QT syndrome;
Postmortem; Resuscitation; Sudden arrhythmic death syndrome; Sudden
cardiac death; Sudden unexplained death; Ventricular arrhythmia
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LOE5 Level of Evidence; MRI5magnetic resonance imaging; OH-
CA5 out-of-hospital cardiac arrest; PVC5 premature ventricular
complex; RWI5 relationship with industry and other entities;
SAD(S)5 sudden arrhythmic death (syndrome); SCA5 sudden car-
diac arrest; SCD5 sudden cardiac death; SUD5 sudden unex-
plained death (Heart Rhythm 2020;-:1–46)
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Top 10 Take-Home Messages
1. Sudden cardiac death (SCD) is an important public health
issue and warrants further study to better quantify its
occurrence, its impact on society, and the opportunities
for improving outcomes through public education and
provision of automated external defibrillators and cardio-
pulmonary resuscitation (CPR) training.
2. For survivors of sudden cardiac arrest (SCA), victims of
sudden unexplained death (SUD), and their relatives, a
multidisciplinary team is central to thorough investiga-
tion, so as to maximize the opportunity to make a diag-
nosis. Where there has been an SCD or resuscitated
SCA and a genetic cause is suspected, genetic testing
and counseling is essential for families, to ensure that
risks, benefits, results, and the clinical significance of ge-
netic testing can be discussed.
3. The psychological care of families affected bySUD and sur-
vivors of SCA (and their families) should run in parallel
with the investigation process. Assessment by professionals
trained in psychological care should be offered, as well as
grief counseling and peer support, where appropriate.
4. For the investigation of SUD, a detailed personal and fam-
ily history is essential, with attention to sentinel symptoms
during life such as syncope or seizures, witness accounts,
premorbid investigations, and inspection of any cardiac
rhythm monitoring around the time of death.
5. A comprehensive autopsy is an essential part of the inves-
tigation of SUD and should include collection and storage
of tissue suitable for genetic analysis. When the autopsy
suggests a possible genetic cause, or no cause and the
heart is normal, referral to a multidisciplinary team for
further investigation is indicated.
6. For victims of SCD or survivors of cardiac arrest where the
phenotype is known, genetic testing of the proband focused
on likely candidate genes, along with clinical evaluation of
family members, aids in identifying family members with,
or at risk of developing, the same condition.
7. For victims of SCD or survivors of cardiac arrest where
the phenotype is not known, arrhythmia syndrome–
focused genetic testing may help arrive at a secure diag-
nosis, whereas wider testing without careful consideration
References ......................................................... 39
Appendix 1 Author Disclosure Table .............. 47
Appendix 2 Reviewer Disclosure Table ........... 50
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of the implications of indeterminate results by experi-
enced clinicians may only serve to add uncertainty and
lead to misinterpretation of results.
8. For the investigation of SCA survivors, essential inquiry in-
cludes detailed personal and family history, witness ac-
counts, physical examination, multiple electrocardiograms
(ECGs), and cardiac imaging. Ambulatory monitoring
and/or provocative testing (exercise, pharmacological, and
invasive electrophysiological) may provide additional use-
ful information. A sample suitable for future DNA testing
should be taken early in the patient’s course and stored.
9. Genetic investigation of SCA survivors is best under-
taken at a center with multidisciplinary care infrastruc-
ture and should focus on likely candidate genes known
to be causally related to the suspected phenotype. In
some cases, genetic evaluation without a suspected
phenotype may be undertaken with appropriate genetic
counseling, although genetic evaluation of patients
with a known nongenetic cause of cardiac arrest is
discouraged.
10. The investigation of the families of victims of SUD and
survivors of SCA should include clinical and, if known,
genetic cascade testing. If the cause of SUD (or rarely,
SCA) is unknown, then clinical investigation of first-
degree relatives may include physical examination,
ECGs, cardiac imaging, ambulatory monitoring, and pro-
vocative testing (exercise, pharmacological, and rarely
invasive electrophysiological) with multidisciplinary
team supervision. Follow-up and periodic re-evaluation
are important and are directed by initial findings.
Section 1 Introduction
1.1. Purpose
This expert consensus statement represents an international
multidisciplinary effort led by the Asia Pacific Heart
Rhythm Society (APHRS), in partnership with the Heart
Rhythm Society (HRS) and in collaboration with the Asso-
ciation for European Cardiovascular Pathology (AECVP),
the European Heart Rhythm Association (EHRA), the Euro-
pean Society of Human Genetics (ESHG), the Latin Amer-
ican Heart Rhythm Society (LAHRS), the National Society
of Genetic Counselors (NSGC) (USA), the Pediatric and
Congenital Electrophysiology Society (PACES), and the
European Reference Network for Rare and Low Prevalence
Complex Diseases of the Heart: ERN GUARD-Heart. The
intent is to provide clinicians with practical patient-
centered recommendations for evaluating patients with sud-
den cardiac arrest (SCA), decedents with sudden cardiac
death (SCD), and their families, based on all available evi-
dence. Although the recommendations are for optimal
care, the writing committee recognizes that not all resources
will be available to all clinicians. Nevertheless, this docu-
ment articulates the evaluation that the clinician should
aspire to provide.
1.2. Organization of the Writing Committee
The writing committee consisted of internationally recog-
nized experts from 14 countries in the fields of cardiac elec-
trophysiology, cardiology, pediatric cardiology, genetic
counseling, community genetics and public health genomics,
and cardiac pathology, representing APHRS, HRS, AECVP,
EHRA, ESHG, LAHRS, NSGC, PACES, and ERN
GUARD-Heart and selected according to each society’s pro-
cedures. In addition, a patient representative was chosen to
provide a consumer viewpoint. Each partner society nomi-
nated a chair, who did not have relevant relationships with in-
dustry and other entities (RWIs). In accordance with the
APHRS policies, disclosure of any RWIs was required
from the writing committee members (Appendix 1) and
from the peer reviewers (Appendix 2); of the 28 committee
members, 23 (82%) had no relevant RWIs. Recommenda-
tions were drafted by the writing committee members who
did not have relevant RWIs.
1.3. Methodology and Evidence Review
After development of a preliminary outline, committee mem-
bers were given writing assignments and a schedule of con-
ference calls. Writing committee members conducted a
comprehensive evidence search using MEDLINE/PubMed,
Embase, and the Cochrane Library and summarized the evi-
dence in standardized tables (Appendix 3), with attention to
the study type, size, inclusion criteria, and key findings.
The writing committee reviewed evidence and established
consensus to generate recommendations, which are presented
in a modular knowledge chunk format, with each chunk
including a table of recommendations, a brief synopsis,
recommendation-specific supportive text, flow diagrams or
tables as appropriate, and references. Recommendations
were formulated according to the American College of Car-
diology (ACC)/American Heart Association (AHA) Class
of Recommendation (COR) and Level of Evidence (LOE)
system1 (Table 1) and were subject to a period of public
comment. The COR indicates the strength of a recommenda-
tion based on assessment of the estimated benefits and risks;
LOE rates the quality of evidence that supports the recom-
mendation based on type, quantity, and consistency of data
from clinical trials and other sources. Case reports were not
used to support recommendations. The threshold for
consensus was considered as 80% or higher agreement.
The 74 recommendations were balloted by the 28 writing
committee members and approved by an average of 94%.
A quorum of two-thirds of the writing committee was met
for all votes.
1.4. Document Review and Approval
After review by the entire writing committee, the recommen-
dations were opened for public comment; the draft document
was reviewed by the International Scientific Document
Writing Committee of the APHRS and the Scientific and
Clinical Documents Committee of the HRS and was revised
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prior to external review. The document underwent external
peer review by reviewers appointed by the APHRS and
HRS and each of the collaborating societies. After subse-
quent revisions and endorsement by the participating soci-
eties, the document was ready for publication.
1.5. Scope of the Document
This document provides a framework for the investigation of
1) patients with SCA, 2) decedents with sudden unexplained
death (SUD), and 3) families of both SCA survivors and SUD
victims, as many conditions responsible for the cardiac arrest
or unexplained death may be familial. Identifying a cause is
important for preventing further events in the family, should
an inherited condition be found. Integral to the process is the
counseling of the patients and families, not only because of
the emotionally charged subject, but because finding (or
not finding) the cause of the arrest may influence the futures
of the family members. The disciplines of cardiology, pediat-
rics, radiology, pathology, counseling, psychology, and ge-
netics are all involved in this process. Therefore, the
formation of multidisciplinary teams is essential to provide
a complete service to the patients and their families.
While this document endeavors to provide clinicians with
practical recommendations for evaluating patients with SCA,
Table 1 ACC/AHA recommendation system: Applying Class of Recommendation and Level of Evidence to clinical strategies,
interventions, treatments, and diagnostic testing in patient care*
Reprinted with permission from the American College of Cardiology (ACC) and the American Heart Association (AHA).
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decedents with SUD, and their families, the best approach
will vary with the situation and will be influenced by, for
example, the subject’s age and results of initial testing.
Although some of the recommendations do specify an age
cutoff, it is recognized that this age is somewhat arbitrary
and may not be always appropriate for the disease being
investigated for or the demographics of the patient’s country.
Nevertheless, where an age is specified in a recommendation,
it has passed the consensus voting of the writing group.
Referral to a center with a multidisciplinary team experienced
in such evaluations is recommended because it can facilitate
navigation of these complexities. A multidisciplinary team
can also help organize interval follow-up evaluations for
SCA survivors and their family members. Repeated interval
follow-up can reveal important new clinical data and allows
for integration of new knowledge into the continued evalua-
tion and care of these patients. The writing committee mem-
bers recognize that not all investigative modalities
recommended will be available in all circumstances; howev-
er, this document is an attempt to outline an approach to
which the clinician should aspire.
1.6. Relevant Clinical Practice Documents
Table 2 lists pertinent guidelines and consensus statements
that the writing committee considered for this document.
The included documents contain relevant information for
the diagnosis of patients with SCA and SCD.
1.7. Definitions
The terms used in the consensus statement are defined in
Table 3.
Table 2 Relevant clinical practice documents
Title Publication year
European Recommendations Integrating Genetic Testing into Multidisciplinary Management of Sudden Cardiac Death2 2019
2019 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Catheter Ablation of Ventricular Arrhythmias3 2019
2019 HRS Expert Consensus Statement on Evaluation, Risk Stratification, and Management of Arrhythmogenic
Cardiomyopathy4
2019
2018 ESC Guidelines for the Diagnosis and Management of Syncope5 2018
2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden
Cardiac Death6
2017
Pre-participation Cardiovascular Evaluation for Athletic Participants to Prevent Sudden Death: Position Paper from
the EHRA and the EACPR, Branches of the ESC7
2016
2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac
Death8
2015
EHRA/HRS/APHRS Expert Consensus on Ventricular Arrhythmias9 2014
HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary
Arrhythmia Syndromes10
2013
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and
Cardiomyopathies11
2011
Table 3 Definitions
Term Definition
Sudden cardiac arrest
(SCA)
Sudden cessation of cardiac activity with hemodynamic collapse, typically due to sustained ventricular
arrhythmia
Sudden cardiac death
(SCD)
Death that occurs within 1 hour of onset of symptoms in witnessed cases, and within 24 hours of last being seen
alive when it is unwitnessed
Sudden unexplained death
(syndrome) (SUD[S])
Unexplained sudden death occurring in an individual older than 1 year
Sudden unexplained
death in infancy
(SUDI)
Unexplained sudden death occurring in an individual younger than 1 year with negative pathological and
toxicological assessment
Note: Synonymous with “sudden unexplained infant death” (SUID)
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Section 2 Epidemiology
2.1. Epidemiology: Sudden Death
"Sudden unexplained death" refers to an unexpected and sud-
den death in an individual older than 1 year. Sudden death
occurring unexpectedly within the first year of life is termed
“sudden unexplained death in infancy” (SUDI). Multiple def-
initions have been in use over the past decades, although
most recent studies implement a definition that differs be-
tween witnessed and unwitnessed events; in witnessed cases,
death has to occur within 1 hour of change in cardiovascular
status, whereas unwitnessed cases have to be seen alive and
functioning normally within 24 hours of being found
dead.12,13
SCD constitutes the majority of SUD.14-16 Reported overall
SCD incidence rates vary across studies and countries, in part
due to large difference in SCD definitions and methods for
estimation of SCD rates. Previous studies report overall SCD
rates ranging from 15 to 159 SCD per 100,000 persons per
annum, corresponding to 6–20% of all deaths.17-24 However,
both incidence and causes of SCD vary markedly with age.
Lowest SCD incidence is observed in children and
adolescents.15,18,25-28 SCD incidence is low in children and
the young under 35 years and increases dramatically up until
the age of approximately 60–80 years.15,19,20,29,30
In young persons aged 1–35 years, most SCDs are caused
by potentially inherited heart diseases, including primary ar-
rhythmogenic disorders (eg, congenital long QT syndrome
and catecholaminergic polymorphic ventricular tachycardia
[CPVT]), hypertrophic cardiomyopathy, arrhythmogenic car-
diomyopathy, and dilated cardiomyopathy;15,18,25-29,31,32
however, coronary artery disease, anomalous coronary
arteries, aortic dissection, congenital heart disease, and
myocarditis are also potential causes, potentially with a
non-negligible genetic component (Figure 1). From the age
of 35 years, coronary artery disease becomes the most com-
mon cause of SCD, although potentially inherited heart dis-
eases remain a common cause of SCD at least until the age
of 50 years.27,29,33 Individuals with SUD who subsequently
have negative pathological and toxicological assessment
may be assumed to have sudden arrhythmic death (syn-
drome), or SAD(S), a term synonymous with “autopsy-nega-
tive SUD.”
At any age, males have higher SCD rates compared with
females, even after adjustment for risk factors of coronary
heart disease.34 Ethnic background seems to have large ef-
fect.35,36
Synopsis
SUD is a tragedy and, in the case of an underlying genetic
predisposition, may be preventable. The main cause of SUD
is SCD. SCD in the young often occurs in people who were
thought to be well, may occur without warning symptoms,
and is often the first presentation of an underlying genetic
heart disease. Across all ages, estimates differ from 5% to
20% of all deaths, and ethnicity-specific data on SCD inci-
dences worldwide are sparse. Cause of death changes accord-
ing to age (Figure 1). Exact estimates of the burden of SCD
are crucial in order to adjudicate public health spending.
Recommendation-Specific Supportive Text
1. and 2. Inherited cardiac disorders are the main cause of
SCD in the young. Sudden death is SCD in 60–90% de-
pending on age, of which the majority is potentially
from inherited cardiac disease.2,15,40 Exact estimates of
the burden of SCD are crucial in order to adjudicate public
health spending.25
Table 3 (Continued )
Term Definition
Sudden arrhythmic death
(syndrome) (SAD[S])
Unexplained sudden death occurring in an individual older than 1 year with negative pathological and
toxicological assessment
Note: Synonymous with “autopsy-negative sudden unexplained death”
Sudden unexplained
death in epilepsy
(SUDEP)
Sudden and unexpected, nontraumatic and nondrowning death of a person with epilepsy, without a
toxicological or anatomical cause of death detected during the postmortem examination
Recommendations for improving outcomes from sudden death
COR LOE Recommendations References
1 B-NR 1. Investigation of SUD at a young age should be made a public health priority due to the
combined prevalence of inherited cardiac diseases of at least 1:500, the years of potential
life lost, and the significant impact on the family and community; therefore, public funding
should be allocated for relevant investigations.
15,25,37
1 C-EO 2. Identification of inherited cardiac conditions that predispose to SCD should be made a public
health priority, as diagnosis may prevent future cardiac events in affected family members.
1 B-NR 3. The burden of SUD and varied outcomes in relation to sex, different ethnic populations, and
socioeconomic backgrounds should be investigated worldwide.
35,36,38,39
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3. Estimates of SCD among different ethnic backgrounds are
sparse worldwide.35,36,38,39
2.2. Epidemiology: Sudden Cardiac Arrest
Survivors
2.2.1. Background
Out-of-hospital cardiac arrest (OHCA) is a leading cause of
mortality globally41-43 and is defined as the loss of
functional cardiac mechanical activity in association with
an absence of systemic circulation, occurring outside of a
hospital setting. The exact burden of OHCA remains
unknown, since a considerable number of cases are not
attended by emergency medical services (EMS) and
regional variations are prevalent in both reporting systems
and survival.17,44,45 Approximately 275,000 people in Eu-
rope have cardiac arrest treated by EMS per year, with only
29,000 (10.5%) surviving hospital discharge.46 In England,
28,729 EMS-treated OHCA cases were reported in 2014
(53 cases per 100,000 of the resident population), with only
7.9% surviving to hospital discharge.47 In the United States,
reports from 35 communities suggested an incidence of 55
per 100,000 person-years48 or approximately 155,000 indi-
viduals having an EMS-treated all-rhythm OHCA per
year.48 Globally, the weighted incidence estimates per
100,000 person-years of EMS-treated OHCA are 34.4 in Eu-
rope, 53.1 in North America, 59.4 in Asia, and 49.7 in
Australia. For reported survival estimates, the percentage sur-
vival to discharge was 7.6% in Europe, 6.8% in North Amer-
ica, 3.0% in Asia, and 9.7% in Australia.42
Significant geographical variation in the incidence of
OHCA associated with poor outcomes has remained un-
changed in the past 3 decades.17,41,42,44 However, implemen-
tation of coordinated efforts targeted at improving the local
chain of survival in some cities has improved regional sur-
vival to 20–40%.49,50 This survival benefit can be partially
attributed to varying definitions of OHCA,42 but it is primar-
ily due to a coordinated effort to optimize the effectiveness of
the local chain of survival.51 Identifying and improving weak
links in the local chain of survival, paired with targeted ap-
proaches to improve the effectiveness, has resulted in posi-
tive outcomes achieved in several geographic regions.49,52-54
2.2.2. Causes of Out-of-Hospital Cardiac Arrest
OHCA causes are classified into cardiac and noncardiac
causes.47,55,56 Approximately 80% of individuals presenting
with OHCA reached by EMS, and in whom resuscitation is
considered possible, have a cardiac cause.56
OHCA can affect seemingly fit and healthy athletes,
young adults, or children. The incidence of SCD in athletes
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Figure 1 Distribution of causes of death among autopsied cases of sudden cardiac death (n 5 753) according to age in persons aged 1–49 years in Denmark
(J.T.-H., unpublished data). SADS5 sudden arrhythmic death syndrome. *Coronary artery disease, especially in young persons, may be due to inherited disease
(eg, familial hypercholesterolemia).
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can range from 1 in 23,000 to 1 in 200,000 athletes per year,
depending on a number of factors including populations stud-
ied.57,58 In a retrospective analysis of the Rescu Epistry data-
base of consecutive OHCA attended by EMS in a specific
area of Ontario, Canada, the incidence of SCD during partic-
ipation in competitive sports was reported to be 0.76 cases
per 100,000 athlete-years.59 The main causes of SCD were
stratified by age. In those younger than 35 years, structural
heart and primary arrhythmic causes were most common.
In those aged between 35 and 45 years, coronary artery dis-
ease was the most frequent underlying pathology.59 In a pro-
spective study of children and young adults aged 1–35 years,
490 cases of SCD were identified from centers in Australia
and New Zealand.25 The cause of death was unexplained in
40% of these cases at autopsy, in whom a structurally normal
heart was reported.25 In this study, the annual incidence of
SCD was calculated to be 1.3 cases per 100,000 people.
When stratified according to age group, the highest incidence
(3.2 cases per 100,000 people per year) was observed in those
aged 31–35 years. Coronary artery disease was the most com-
mon cause ascribed. Younger age and SCD occurring at night
were independently associated with unexplained SCD, prob-
ably due to congenital channelopathies. Less common causes
were inherited cardiomyopathies (eg, dilated, hypertrophic,
and arrhythmogenic right ventricular), myocarditis, and
aortic dissection.
The Cardiac Arrest Registry to Enhance Survival
(CARES), established by the Centers for Disease Control
and Prevention (CDC),60 evaluated OHCA events of pre-
sumed cardiac etiology that involve persons who received
resuscitative effort. OHCA is defined in CARES as a cardiac
arrest that occurred in the prehospital setting, had a presumed
cardiac etiology, and involved a person who received resus-
citative efforts, including cardiopulmonary resuscitation
(CPR) or defibrillation. The registry includes 40,274
OHCA records, of which 31,689 OHCA events were pre-
sumed to be of cardiac etiology (eg, myocardial infarction
or arrhythmia) that received resuscitation efforts in the preho-
spital setting (mean age 64.0 years [SD 18.2]; 61.1% male).
The survival rate to hospital admission was 26.3%, and the
overall survival rate from cardiac arrest to hospital discharge
was 9.6% (Figure 2). Approximately 36.7% of OHCA events
were witnessed by a bystander. Only 33.3% of all patients
received bystander CPR, and only 3.7% were treated by by-
standers with an automated external defibrillator (AED)
before the arrival of EMS providers.
The group most likely to survive an OHCA is persons
who are witnessed to collapse by a bystander and found
in a shockable rhythm (ie, arrhythmias leading to ventricu-
lar fibrillation or pulseless ventricular tachycardia).60
Among this group, survival to discharge was 30.1%
(Figure 3). A subgroup analysis, performed among persons
who experienced OHCA events unwitnessed by EMS, re-
vealed that whites were significantly more likely to receive
CPR than blacks, Hispanics, or members of other racial/
ethnic populations (p, 0.001). Overall survival to hospital
discharge of patients whose events were not witnessed by
EMS personnel was 8.5%. Of these, patients who received
bystander CPR had a significantly higher rate of overall
survival (11.2%) than those who did not (7.0%)
(p , 0.001).
Figure 4 shows bystander CPR and lay AED use by per-
centage of black residents in the area. Directing attention to-
ward improving education, availability of AEDs, and
treatment of cardiac arrest in predominantly black neighbor-
hoods may save lives.39
Bystander AED use in OHCA in pediatric populations is
variable and uncommon, with important variations based on
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Figure 2 Cumulative overall survival rates, by participating emergency medical services agency—Cardiac Arrest Registry to Enhance Survival (CARES),
United States, October 1, 2005–December 31, 2010. Agencies sorted by total number of out-of-hospital cardiac arrest events in CARES (from low to high; range:
18–5,434).60
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neighborhood characteristics leading to marked disparities in
survival and outcomes. Griffis et al.38 reported that AED use
(likely due to availability) was more common in neighbor-
hoods with a median household income of .$50,000 per
year (12.3%; p 5 0.016), ,10% unemployment (12.1%; p
5 0.002), and .80% high school education (11.8%; p 5
0.002). Greater survival to hospital discharge and neurologi-
cally favorable survival were among arrests with bystander
AED use, varying by neighborhood characteristics.
2.2.3. Public Health Implications
The majority of persons who experience an OHCA event, ir-
respective of etiology, do not receive bystander CPR or other
timely interventions that are known to improve the likelihood
of survival to hospital discharge (eg, defibrillation).54
Because nearly half of cardiac arrest events are witnessed, ef-
forts to increase survival rates should focus on timely and
effective delivery of interventions by bystanders and EMS
personnel (Figure 5).
Education of public officials and community members
regarding the importance of increasing rates of bystander
CPR and promoting the use of early defibrillation by lay and
professional rescuers is critical to increasing survival rates. Re-
porting at local and national levels can enable local and na-
tional public health and EMS agencies to coordinate their
efforts to target improving emergency response for OHCA
events, regardless of etiology, which can lead to improvement
in OHCA survival rates (Figure 6).
Synopsis
OHCA remains a significant cause of mortality globally.
Despite implementation of cardiac arrest protocols including
CPR training and AEDs, only 33% of witnessed OHCA cases
receive bystander CPR and less than 4% are defibrillated
onsite. OHCA hospital discharge survival remains dismal
at around 10% and has remained stagnant for the past 3 de-
cades. Significant geographic variation in OHCA incidence
and the role of social disparities merit further research. Public
p
ri
n
t
&
w
e
b
4
C
=
F
P
O
Figure 3 Cumulative Utstein survival rates (patients alive when arriving to hospital) by participating emergency medical services agency—Cardiac Arrest
Registry to Enhance Survival (CARES), United States, October 1, 2005–December 31, 2010. Agencies sorted by total number of out-of-hospital cardiac arrest
events in CARES (from low to high).60 †Utstein survival refers to survival to hospital discharge of persons whose cardiac arrest events were witnessed by a
bystander and had an initial rhythm of ventricular fibrillation or pulseless ventricular tachycardia (range: 0–598).
Recommendations for improving outcomes in SCA survivors
COR LOE Recommendations References
1 B-NR 1. Targeted CPR training should be widely implemented with particular emphasis on low-income
communities, ethnic minorities, and middle- to low-income countries.
38,60
1 B-NR 2. The burden of out-of-hospital SCA and varied outcomes in different ethnic populations and
socioeconomic backgrounds should be investigated worldwide.
35,38,39
1 B-NR 3. Appropriately maintained AEDs should be readily available at schools, stadiums, public
transport stations, casinos, etc, as well as venues where no other access to AEDs is available
(eg, trains, ships, planes), with appropriate training of users.
61,62
10 Heart Rhythm, Vol -, No -, - 2020
PGL 5.6.0 DTD  HRTHM8562_proof  22 October 2020  3:16 am  ce
health campaigns promoting CPR training in at-risk commu-
nities and greater availability of AEDs are needed.
Recommendation-Specific Supportive Text
1. Coordinated efforts targeted at improving the local chain
of survival have improved regional survival.49,50 Targeted
approaches to improve the effectiveness of CPR have
resulted in positive outcomes.52-54 The group most
likely to survive an OHCA is persons who are
witnessed to collapse by a bystander and found in a
shockable rhythm, so widespread CPR training is
recommended. Subgroup analysis has revealed that
whites were significantly more likely to receive CPR
than other racial/ethnic populations.60 AED use was
more common in neighborhoods with high median house-
hold income, ,10% unemployment, and .80% high
school education.38 Therefore, maximum benefit will be
gained from targeting CPR training to groups of high so-
cioeconomic need and ethnic minorities.
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Figure 5 Bystander-witnessed arrest, bystander cardiopulmonary resuscitation (CPR), shockable heart rhythm as first recorded rhythm, and survival on arrival
at the hospital, Denmark, 2001–2010. Reprinted with permission from the American Medical Association.54
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Figure 6 Examples of complimentary bystander cardiopulmonary resus-
citation (CPR) programs. Reprinted with permission from Elsevier.64
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Figure 4 Bystander treatments of patients with out-of-hospital cardiac ar-
rest before emergency medical services arrival among neighborhoods by per-
centage of black residents. Reprinted with permission from the American
Medical Association.39 AED5 automated external defibrillator; CPR5 car-
diopulmonary resuscitation.
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2. The burden of OHCA and the response of bystanders ap-
pears to vary according to ethnicity and socioeconomic
status.35,38,39,60 Further investigation of these findings
may result in targeted approaches to maximize outcome
from investment when aimed at these communities.
3. Availability of AEDs has been shown to improve sur-
vival.61-63 Therefore, as the majority of cardiac arrests
are witnessed, AEDs at schools, stadiums, stations, etc,
may be expected to increase survival. Venues where
delivery of AEDs by emergency services is unlikely (eg,
trains, ships, planes) are of particular importance.
Appropriately maintained equipment and appropriate
training of potential AED users are an essential
component of this strategy.
Section 3 Multidisciplinary Team
3.1. Introduction
The investigation of SCD and resuscitated SCA requires
input from a variety of different disciplines. The coordination
and the communication between themmandate the formation
of a multidisciplinary team. Numerous consensus statements
agree on the importance of a dedicated combined cardiac ge-
netic service in this setting.2,11,65-67
3.2. Key Features of an Effective Multidisciplinary
Team
Certain key features can be identified in well-functioning
multidisciplinary teams across specialties. Nancarrow
et al.68 propose 10 key attributes including positive leader-
ship and management, communication strategies and struc-
tures, appropriate resources, appropriate skill mix, and a
supportive team climate with a focus on education of each
other. There should be open communication and shared deci-
sion-making.
The detection of inherited heart conditions by pathologists
and by hospital clinicians requires heightened awareness of
their existence and a simple referral pathway to a multidisci-
plinary service with cardiac genetic expertise. Clinical expe-
rience shows that the appointment of a coordinator, as well as
an enthusiastic team leader, is essential to facilitate this pro-
cess, and regular meetings increase relevance and improve
attendance69 (Figures 7 and 8).
3.3. Defining Which Disciplines Should Be
Represented
The investigation of SUD is led by (forensic) pathology and
the investigation of resuscitated SCA by pediatric or adult
cardiology, with cardiac heart rhythm specialists and genetic
cardiologists often being central. Clinical and molecular ge-
netic specialists and genetic counselors are needed because
of the significant role of molecular genetics in achieving a
diagnosis and cascade screening, the consideration of multi-
system genetic syndromes, and the high prevalence of ge-
netic variants of uncertain significance.70,71 The high levels
of psychological morbidity among SCA survivors and family
members of both SCA survivors and decedents mandates ac-
cess to psychology expertise,72-74 and input into the
multidisciplinary team helps keep this in focus.75 The pres-
ence of a specialist cardiac genetic nurse in the cardiology
inpatient setting increases detection of inherited cardiac con-
ditions following SCA.76 Other clinical specialists can be
helpful and be drafted in for certain cases—neurologists, pe-
diatricians, metabolic specialists, and intensivists, for
example.
3.4. Coordination Across Disciplines and Other
Boundaries
The fact that the many disciplines may not be co-located
highlights the importance of a coordinator to a multidisci-
plinary service. Co-location is not critical for effective collab-
oration, and non-co-location should not be an excuse for
failed collaboration. A regional or institutional coordinator
could be a nurse specialist, genetic counselor, or other allied
professional and is vital to facilitate team meetings and
communication between specialists and between centers,
with primary care and across regions or between states and
countries where necessary to facilitate family screening69,77
(Figure 7).
3.5. Links to Other Services
Links to other services as proposed in a recent scientific state-
ment66 and practiced by some centers already69 include con-
nections to molecular genetic expertise, researchers, primary
health providers, between regions, and to a cardiac genetic
clinical registry to facilitate family screening and follow-up
across traditional boundaries (Figure 8).
Clinical and genetic registries are generally voluntary and
consent-based and have a research element. We do not
consider that they are compulsory. However, in this setting
they do have particular relevance because many cases remain
unresolved after the initial investigation and families may
find comfort in knowing that efforts to find a diagnosis
continue. The multidisciplinary team also provides a mecha-
nism to revisit family members if new findings appear in the
wider family or if the pathogenicity of a genetic variant is re-
defined.
12 Heart Rhythm, Vol -, No -, - 2020
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Synopsis
The cardiac and genetic investigation of SUD and resusci-
tated SCA should be overseen by a multidisciplinary team
with appropriate expertise in this area. Recommendations
include adequate resourcing, a dedicated coordinator, strong
leadership, and amutually supportive team thatmeets regularly.
Recommendation-Specific Supportive Text
1. For regions where coordinated cardiac genetic services
exist that include the investigation of SUD, detection of
inherited heart conditions is higher than in regions where
they are not.78 Families prefer specialized clinics that
combine co-located cardiac and genetic expertise and ge-
netic counseling.79 Many such dedicated clinics interna-
tionally have led to the detection of inherited heart
conditions following SCD and resuscitated SCA.80-82 It
is therefore logical that multidisciplinary teams should
have links to such clinics. Continued productive
dialogue among pathology, coronial, police, and cardiac
genetic services is recommended to improve the quality
and relevance of forensic pathologists’ reports.86
2. Genetic testing in this context leads to a significant pro-
portion of both pathogenic and unclassified variants, and
precise evaluation of clinical phenotype is imperative
for the correct assignation of such variants, so that a ser-
vice that combines specialist cardiology and genetic
expertise is essential.83,84 Specialized clinics that combine
co-located cardiac and genetic expertise and genetic coun-
seling are preferred,79 and such combined clinics have a
high detection of inherited cardiac conditions following
resuscitated SCA.82,85
Section 4 Counseling Families, the Bereaved and
the Nearly Bereaved
Genetic counseling is a process that aims to assist patients
and their families to understand and adapt to the medical,
psychosocial, and familial impact of inherited diseases.87,88
Genetic counseling goes beyond the discussion of genetic
testing and is important for all patients with a genetic condi-
tion, at all stages of management.89 Although genetic coun-
seling may be performed by any number of health
professionals, genetic counselors are specifically trained in
this role and have grown to a large allied health workforce
worldwide.90,91 In some institutions, this role may be per-
formed by a clinical/medical geneticist, genetic nurse, or
other appropriately trained specialist.
In the setting of SCD or resuscitated SCA where a genetic
cause is suspected, the inclusion of genetic counselors in the
multidisciplinary team is widely advocated. The role of the
cardiac genetic counselor includes taking a detailed family
history, investigating and confirming details such as post-
mortem reports, providing education and awareness, assist-
ing in coordinating family clinical screening, and providing
psychosocial support.74,92-95 Throughout the process of
genetic testing, genetic counselors provide important pre-
and post-test genetic counseling, assist with interpretation
of the results, help communicate this information to relatives,
and assist with cascade genetic testing75,93,96,97 (Table 4).
Where there are significant emotional difficulties (see Sec-
tion 5), the process of effectively conveying genetic informa-
tion can be challenging.98 For families who have experienced
a young SCDwhere a genetic cause is suspected, learning the
potential inheritance risk to family members and need for
clinical screening can add an additional stressor at a time of
intense grief. Furthermore, with the increasing availability
of postmortem genetic testing (see Sections 6.4 and 6.5),
the need for complex genetic discussions with families is
more commonplace.99 Genetic counseling prior to and after
genetic testing is important, particularly where genetic test re-
sults are not straightforward such as identification of variants
of uncertain significance or in the event of a variant reclassi-
fication.100,101
There is wide acknowledgment that genetic counseling as
a process should go beyond just provision of informa-
tion.102,103 The psychosocial aspects of genetic counseling
include psychological support, empathic listening, crisis
intervention skills, knowledge of family dynamics, coping
models, processes of grief, and adjustment to disease diagno-
ses, all of which align with the core competencies of genetic
counseling accreditation.104,105 Attending to the psychoso-
cial needs, in addition to provision of education and informa-
tion, has been demonstrated to positively impact patient
outcomes, largely based around knowledge and recall, but
healthy adjustment, empowerment, behavioral change, and
satisfaction with decision-making also reduce anxiety and
worry.103,104,106,107
Recommendations for the role of a multidisciplinary team for investigation of SUD and SCA
COR LOE Recommendations References
1 B-NR 1. The investigation of SUD and SCD due to a potentially heritable condition should be overseen
by a multidisciplinary team with, as a minimum, appropriate expertise in pediatric and/or
adult cardiology, genetics, genetic counseling, and pathology.
78-82
1 B-NR 2. The investigation of a sudden cardiac arrest survivor where a heritable condition is possible
should be overseen by a multidisciplinary team with, as a minimum, appropriate expertise in
pediatric and/or adult cardiology, genetics, and genetic counseling.
79,82-85
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Synopsis
Genetic counseling of patients and their families with ge-
netic conditions is recommended, including those with SCD
or resuscitated SCA where a genetic cause is suspected. Key
aspects of the process include discussion of inheritance risks,
education and awareness, pre- and post-test genetic coun-
seling, interpretation of genetic results, taking a family his-
tory, coordination of clinical screening, and psychosocial
support. Genetic counseling is focused on both information
provision and psychosocial support and together has been
shown to improve knowledge and recall; promote healthy
adjustment, empowerment, and behavioral change; increase
satisfaction with decision-making; and reduce anxiety and
worry. While genetic counseling is a process often performed
by a variety of health professionals, ideally a specifically
trained genetic counselor or genetic nurse with appropriate
skills in information provision and psychosocial support
would perform this role.
Recommendation-Specific Supportive Text
1. Genetic counseling includes both information provision
and psychosocial support. It is ideally performed by health
professionals with specific training and experience; this
includes genetic counselors, genetic nurses, or other qual-
ified health professionals. 80-82,84,85,103,106,107,109
2. In the context of genetic testing, pre- and post-test genetic
counseling must be performed.75,95,96,99 In cases where
there is uncertainty in the findings, such as a variant of un-
certain significance or a variant reclassification, this is of
particular importance.100,101
Section 5 Psychological Care
SCDwhere a genetic cause is suspected has a profound psycho-
logical impact on the survivingmembers of the family.Grief is a
normal emotional response to the loss of a lovedone. Individuals
will grieve differently, and while there is no single trajectory,
Recommendations for counseling families affected by SUD and SCA
COR LOE Recommendations References
1 B-NR 1. Genetic counseling is strongly recommended for all families where there has been an SUD or
resuscitated SCA and a heritable cause is suspected, and should include antemortem and
postmortem data collection and evaluation, so that risks, benefits, results, and the clinical
significance of genetic testing can be discussed.
80-82,84,85,103,
106,107,109
1 C-EO 2. It is recommended that genetic testing in families where an SUD or resuscitated SCA due to a
heritable cause is suspected is performed only with appropriate genetic counseling.
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Figure 7 Referral flow for cardiac genetic investigation of sudden cardiac death (SCD) or resuscitated sudden cardiac arrest (SCA). MDT5multidisciplinary
team.
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Figure 8 Participants in a cardiac genetic service. “Pathologists” includes forensic pathologists. Modified with permission from Elsevier.69
Table 4 Key goals of genetic counseling following sudden cardiac death/resuscitated sudden cardiac arrest
Goal Description
Genetic counseling about
inheritance risks
Provide information tailored specifically to the family about their inheritance risks.
Provide education and
awareness
Educate about inheritance risks, the need for clinical surveillance, and options for genetic testing to
allow the family to make subsequent important medical decisions. Conveying information is not
straightforward, given varying health literacy and competing health concerns; however, genetic
counseling can support effective communication.108 Genetic counseling can also include
connection of families with advocacy organizations and relevant research studies.
Pre- and post-test genetic
counseling
Explain the process and discuss the options of genetic testing, all possible outcomes of testing,
implications for patients and/or their family members, and worries and fears about testing; ensure
consideration of all possible results and implications.109 Care should be taken in conveying test
results of uncertain significance,101,110 specifically ensuring adequate understanding and
confidence to communicate key risk information to family members.
Pre- and post-test genetic
counseling for cascade
testing of asymptomatic
relatives
There are ethical, legal, and social implications when considering cascade genetic testing of
asymptomatic at-risk relatives. Careful pre-test genetic counseling should explore the individual’s
feelings toward their risk, how they might feel if they are gene positive or gene negative, and
implications for their own health and clinical management based on their genetic result. Discussion
about the potential for reclassification of the genetic result is also important.100,111
Provide input regarding
classification of genetic
variants
Knowledge of variant and gene curation processes will enable review of any genetic test findings at all
stages of family management.112 Clinicians involved in family management (including genetic
counselors) are more likely to provide conservative variant classifications compared to clinical
laboratories,113 and processes to guarantee regular review of variants will ensure appropriate
reclassifications are made.114,115
Obtain detailed three-
generation family history and
confirm details
Record family history information in a pedigree and interpret the information and the risk posed to
family members. Taking a detailed family history can allow development of rapport, elucidate family
relationships and social circumstances, and inform clinical care.116
Assist with coordination of family
clinical screening
Ensure adequate understanding of the clinical screening recommendations for family members and
provide assistance with communicating this to relatives as needed. Provide support in organizing
cardiology appointments with appropriate tests.92
Provide psychosocial support
and identify when referral to
clinical psychologist is
required
Although genetic counseling is unlikely to resolve any significant psychopathologies, the process of
providing information and a big picture perspective allowing a patient to normalize their experience
and emotional response can have a positive impact, including patient empowerment.103,106,107
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many will experience disbelief, yearning, anger, sadness, and
acceptance.117 After a death, an individual will not return to
normal, but rather create a revised meaningful life without the
deceased. In a small proportion of bereaved individuals, the
initial grief response does not resolve and may result in pro-
longed grief, or persistent complex bereavement disorder ac-
cording to the Diagnostic and Statistical Manual of Mental
Disorders, 5th Edition (DSM-5).118,119 This occurs in approxi-
mately 7% of the general bereaved population,120 and in 21%
of first-degree relatives following SCD in the young.121 Post-
traumatic stress symptoms can also be experienced by family
members. Posttraumatic stress occurs in response to a specific
trigger, typically one that threatens one’s own or a loved one’s
well-being. It is characterized by avoidance with hyperarousal
and intrusive thoughts, including persistent and extreme fear
and panic similar to that experienced by family members at
the time of the event.122 Posttraumatic stress has been shown
in 44%of first-degree relatives following a young SCD.121 Indi-
viduals with prolonged grief and/or posttraumatic stress symp-
toms can benefit from intervention with a clinical psychologist
or other appropriately trained clinicians, and there is extensive
evidence to support the efficacy of psychological treatments
for these conditions in other settings.120 Further, there is greater
risk of other psychiatric comorbidities,118 suicide,123 and devel-
opment of chronic medical conditions.124
Factors associatedwith poor psychological outcomes have
been investigated. One study showed that mothers of the
deceased were more likely to report anxiety and depression
symptoms.72 In total, 53% of the mothers surveyed reported
probable anxiety disorder on average 4 years after the death.
In a larger study, after adjusting for factors including relation-
ship to the decedent, those familymemberswhowitnessed the
death or discovered the decedent’s body had a 3-fold risk of
posttraumatic stress symptoms (OR 3.3, 95% CI 1.2–8.7, p
5 0.02) and a 4-fold risk of prolonged grief (OR 4.0, 95%
CI 1.3–12.5, p 5 0.02).121 Given that half report symptoms
indicating psychological difficulties, all first-degree relatives
should be offered psychological evaluation and treatment.
Although the evidence for psychological support is derived
from studies investigating SCD where a genetic cause is sus-
pected, it may logically apply to those individuals who have
survived SCA and their families (Figure 9).
There may be initial reluctance to seek psychological sup-
port given community stigma around mental health. Indeed, a
recent study investigating families who had experienced a
young SCD found that only 12% had sought psychological
support, withmost of those being self-referrals.125 In discussing
options for ongoing psychological support with patients and
families, normalizing their response to a significant psycholog-
ical stressor and describing common symptoms of prolonged
grief and posttraumatic stress may reduce any perceived sense
of stigma and increase interest in seeking support.
A recent needs analysis of parentswho had experienced the
SCD of their child (including adult children) found that while
medical information and support were the most important
need, psychological information and support were the most
unmet need.126 Nearly three-quarters reported wanting access
to professional counseling or psychological services. Further,
many indicated access to genetic testing or understanding the
genetic cause to be an important need, highlighting the impor-
tance of maintaining realistic expectations regarding the diag-
nostic yield of postmortem genetic testingwith families.101At
present, this is likely not greater than 15%, and there is a high
likelihood of uncertain genetic findings especially with
increasing gene panel sizes.25,70 A Swedish study of parents
whose children died suddenly between 15 and 35 years of
age likewise showed a critical lack of information and support
in the acute grief stage.127 This included a need for better
communication of the postmortem examination process
(how long it would take, when they would get results), time
with a health professional to discuss the death, and informa-
tion about the cause of death. There was a lack of psycholog-
ical support in the immediate aftermath, with many family
members seeking their own care, including grief counselors
and support groups. The need for support in the early after-
math has been shown to be important in other studies exam-
ining suddenly bereaved parents.128,129
Community or peer-based bereavement support groups
can also enhance social support.120,130 Peer support programs
come in many different forms but always involve people with
similar backgrounds providing emotional, social, or practical
support to each other.131 Peer supporters draw on their shared
experiences to provide empathic understanding, information,
and advice to those they are helping. A key aim is to promote
hope, recovery from illness or trauma, improved life skills,
psychological well-being, and social integration.132 A recent
systematic review of peer support services for bereaved sur-
vivors of the sudden death of a loved one in multiple settings
found evidence of reductions in grief and increased well-
being and personal growth among participants, and improved
personal growth and positive meaning in life among peer pro-
viders.133 There is a current gap in care in addressing psycho-
logical support needs of families after the SCD of a young
relative.
Recommendations for psychological care
COR LOE Recommendations References
1 B-NR 1. In the investigation of SCA where a genetic cause is suspected, it is recommended that
referral be offered for assessment by a health professional trained in psychological
evaluation and treatment to the patient (if survived) and immediate family members.
72,121,126,134
2a C-LD 2. In the investigation of SUD where a genetic cause is suspected, provision of information and
referral to support services such as support workers, grief counseling, and peer support
services can be useful.
127,131-133
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Synopsis
The psychological impact to the family following an SCD
where a genetic cause is suspected can be significant.
Although many family members will navigate their way
through this traumatic experience, up to 44% may require
additional psychological support from an appropriately
trained health professional such as a clinical psychologist.
Addressing community stigma around mental health needs
to be considered and discussed with families. In addition,
support services such as social workers, grief counselors,
psychosocial teams, and peer support groups may be useful
to many families. Whereas the evidence for psychological
support is derived from studies investigating SCD where a
genetic cause is suspected, it may logically apply in those
families where there has been an SCA.
Recommendation-Specific Supportive Text
1. and 2. A clinical psychologist or appropriately trained
health professional includes those equipped to assess
and treat trauma; for example, those experienced in deliv-
ering cognitive behavioral therapies. While the evidence
to date supports a need for psychological support in family
members following a young SCD where a genetic cause is
suspected, this may likewise be important for relatives of a
patient who suffers an SCA.72,121,134 There is a need to
train personnel in psychological care for SUD and SCA,
as this is an area where the need is not currently met.
Section 6 Investigation of Sudden Death
6.1. Investigation of Sudden Death: History—
Personal and Family
Despite being “low-tech” and inexpensive, the history, as a
tool for clinical phenotyping, is the essential and fundamental
basis of approaching a patient with SCA because it can guide
appropriate use and interpretation of other diagnostic modal-
ities. The history should be focused toward both the decedent
proband and also the wider family for evidence of other
potentially affected members prior to investigations. Surviv-
ing family members should be investigated by a multidisci-
plinary team within a specialist program for cardiovascular
genetic disorders with the all appropriate medical, genetic,
and psychological personnel and ability for comprehensive
investigations2,10 (Figure 10).
The proband age may help define potential etiologies;
CPVT and long QT syndrome are typically diseases of the
young, whereas coronary artery disease and cardiomyopa-
thies become more common with age (Figure 1). Although
most deaths occur at rest or during sleep,25 death during exer-
tion may point to specific etiologies such as CPVT, long QT
syndrome type 1, or arrhythmogenic cardiomyopathy. In
addition to a detailed prior medical and medication history
(including potential drugs of abuse), the decedent’s health
in the 24–48 hours preceding death including the presence
of any viral prodrome or fever, as well as any prescribed
medication, may be relevant. Myocarditis secondary to viral
infection may be associated with viral and gastrointestinal
symptoms, and both Brugada syndrome and long QT syn-
drome may be exacerbated by specific pharmacological
agents through further inhibition of ion channel function.135
Fever is a well-recognized trigger of ECG changes and
arrhythmia in Brugada syndrome136 and in some long QT
syndrome subtypes,137 and in young children may be mis-
diagnosed as febrile seizures.138
Between 18% and 45% of sudden death cases may have
experienced prior relevant symptoms, typically palpitations,
chest pain, pre-syncope, or syncope, and may have under-
gone relevant investigations.29,70,139 All medical records
relevant to the sudden death etiology should be sought.
Relevant information from the family history should be
collected by a health professional with specific experience
in cardiovascular genetic disease (preferably a genetic coun-
selor) and by an appropriately trained cardiologist. Symp-
toms and diagnoses in other family members as well as
prior cardiovascular investigations should be sought.
Noncardiac findings may be highly pertinent including unex-
plained epilepsy unresponsive to conventional therapy; skel-
etal muscle weakness; curled hair and subtle palmoplantar
hyperkeratosis/keratoderma (arrhythmogenic cardiomyopa-
thy)140; attention deficit disorder and intellectual disability
(CPVT)141; and history of pneumothoraces, vascular disease,
and gastrointestinal and uterine rupture (vascular Ehlers-
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Figure 9 Psychological care following a sudden cardiac arrest (SCA) or a sudden unexplained death (SUD) where a genetic cause is suspected. Colors corre-
spond to the Class of Recommendation in Table 1.
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Danlos syndrome).142 Any other deaths or major cardiac
events in the family should be recorded including those
related to drowning in good swimmers, unexplained motor
vehicle accidents, and sudden infant death or late fetal
demise. If the SUD was observed, it is useful to collect wit-
ness accounts about the events occurring immediately prior
to the collapse and during any resuscitation attempts.
Synopsis
The personal medical and three-generation family history
provides the initial information on which subsequent investi-
gations will be based. Specific features within the wider fam-
ily may suggest diagnoses and help direct subsequent
investigation. The history should be recorded by
cardiologists, specialist nurses, and geneticists or genetic
counselors experienced in cardiovascular genetic diseases,
ideally within the confines of a multidisciplinary program
that can address the medical, genetic, and psychological
needs of the family (see Section 3).
Recommendation-Specific Supportive Text
1. The personal and three-generation family history may pro-
vide critical information relevant to the etiology of SCD
and provide a starting point for further investigations in
both the decedent proband and surviving family mem-
bers.77 Multiple studies show a significant proportion of
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Figure 10 Investigation of sudden unexplained death: personal and family history. Colors correspond to the Class of Recommendation in Table 1. SCD 5
sudden cardiac death.
Recommendations for investigation of sudden death: personal and family history
COR LOE Recommendations References
1 B-NR 1. In the investigation of SUD, an effort should be taken to obtain detailed personal and three-
generation family history (as a minimum) with the assistance of a multidisciplinary team,
including witness accounts.
25,29,70,77,81,135,
139,143,144
1 B-NR 2. In the investigation of SUD, prior medical records and relevant investigations from the
decedent proband and family members should be retrieved.
25,29,70,77,81,
135,139,143-145
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children and adults experience relevant cardiac symptoms
prior to sudden death,10,25,29,70,135,138,139 and some may
have sought medical attention and undergone investiga-
tions. Available ECGs and cardiac imaging, together
with autopsy findings, may allow a diagnosis to be made
(or excluded) in the proband who, until family investiga-
tions have been performed, is the one definitively affected
member of the family. Noncardiac features and symptoms
may also provide important diagnostic information.140-142
2. Further investigation is necessary where sudden death oc-
curs in specific circumstances such as when a cardiac
event may have triggered an apparently environmental
death. Examples include road traffic accidents with no
apparent cause and drowning in competent swimmers.
The presence and associated investigations for other
noncardiac conditions should also be evaluated, specif-
ically epilepsy. Failure to identify a neurological etiology
or abnormality would suggest seizures may have had a car-
diac etiology. Overlap syndromes exist between true
neurological epilepsy and longQT syndrome type 2.146,147
6.2. Investigation of Sudden Death: Examination
of Premorbid Investigations
Individuals who have succumbed to SUD may have had
pertinent investigations prior to their death that aid in the
diagnosis of the cause of their SUD. Twelve-lead electrocar-
diogram (ECG) is the most useful pre-SUD investigation.
Although long or short QT interval, spontaneous type 1 Bru-
gada pattern, and early repolarization pattern are associated
with fatal arrhythmias due to congenital long QT syndrome,
short QT syndrome, Brugada syndrome, or early repolariza-
tion syndrome,148-152 many patients with SUD without
structural heart disease have a normal or near-normal
ECG,145,153 particularly women.154 Additional ECG findings
suggestive of arrhythmic syncope include bifascicular block;
intraventricular conduction abnormalities (QRS duration
.0.12 s); Mobitz I second-degree atrioventricular block
and first-degree atrioventricular block with markedly
prolonged PR interval; sinus bradycardia (,40 bpm) or
slow atrial fibrillation (,40 bpm); nonsustained ventricular
tachycardia; pre-excited QRS complexes; negative T waves
in right precordial leads or epsilon waves; and left ventricular
hypertrophy,5 any of which may indicate potential diagnoses
of inherited arrhythmia syndromes such as progressive
cardiac conduction defect, familial pre-excitation, arrhyth-
mogenic cardiomyopathy, or hypertrophic cardiomyopa-
thy.4,151 In the general population, premature ventricular
complexes (PVCs) are mostly benign; however, some
frequent or complex PVCs significantly increase the risk of
SCD.155-157 If an ECG is recorded by the AED or EMS
just before SCD, features such as J-wave or ST segment
elevation (especially if augmented after a long pause) may
help in the diagnosis of coronary spasm, early
repolarization syndrome, or Brugada syndrome.158,159 Inter-
pretation of ECGs obtained immediately after resuscitation/
defibrillation should be performed with great caution (see
Section 7.4).
Syncope is a sentinel clinical symptom before SUD and
may prompt investigations subsequently useful in making a
retrospective diagnosis of the cause of SUD. In particular,
the trigger for the syncopal event bears useful information.
Ambulatory ECG monitoring during life may provide clues
to the cause of SUD and should be sought.
If transthoracic echocardiography, cardiac computed to-
mography (CT), or cardiac magnetic resonance imaging
(CMR) are performed during the patient’s life, detailed
review may indicate features of dilated cardiomyopathy,
hypertrophic cardiomyopathy, or arrhythmogenic cardio-
myopathy.160 If blood or other tissue sample has been
taken before SUD, this may be a source of DNA for ge-
netic testing, should there not be a postmortem collection
of tissue.8,11,67,151 Neurological findings such as develop-
mental delay or seizures thought to be suspicious for epi-
lepsy during life may contribute to a diagnosis of a cardiac
channelopathy, such as CPVT or long QT syn-
drome.141,161,162 If a patient with SUD has a cardiovascu-
lar implantable electronic device (CIED) implanted,
postmortem interrogation of the CIED is useful to deter-
mine the cause and timing of SCD.163
Synopsis
During the investigation of SUD, pertinent investigations
performed prior to death can aid in establishing the cause.
Recommendations for investigation of sudden death: examination of premorbid investigations
COR LOE Recommendations References
1 B-NR 1. All relevant cardiac investigations, including 12-lead ECGs, echocardiography, CT, CMR,
genetic analyses, and ambulatory monitoring recorded before SUD, should be reviewed and
analyzed.
145,148-150,
153-158,164
1 B-NR 2. Any blood or DNA sample (eg, blood in EDTA, blood on filter paper card) taken before SUD
should be stored for future genetic analysis.
84,165-167
1 B-NR 3. Neurological events such as seizures suspicious for epilepsy before SUD should be reviewed
and studied for a potential cardiac etiology.
70,146,147,161,
162,168,169
2b C-LD 4. ECG information from the AED or ECG monitor recorded around the time of SCD may be useful
for review and analysis.
158,170
1 B-NR 5. Any implanted cardiac electronic device in an individual with SCD should be reviewed and
analyzed.
163,171,172
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Although ECG features such as QT interval, type 1 Brugada
pattern, and early repolarization may be critical for diagnosis,
many ECGs taken during life will be normal. Ambulatory
ECG monitoring and cardiac imaging should be sought to
provide clues to the diagnosis of SCD. Symptoms attributed
to a neurological cause may be re-evaluated, in collaboration
with neurologists. Any potential DNA sample before SUD
should be stored if tissue is not gained at autopsy. ECG infor-
mation from the AED, emergency services, or CIEDs may
also be useful to determine the cause of SCD.
Recommendation-Specific Supportive Text
1. Investigations during life may provide clues to the cause
of SUD and should be sought to aid in diagnosis.173 These
include resting, exercise and ambulatory ECG tracings,
and cardiac imaging studies (echocardiography, CT, and
CMR).145,148-150,153-158,164
2. Samples for potential DNA testing taken during life may
subsequently prove invaluable should they be the only
source of DNA. Although it is a Class 1 recommendation
that patients with SUD have an autopsy and material for
DNA testing collected (see Section 6.3), it is recognized
that sometimes this is not done, making blood or tissue
samples taken during life the only remaining source for
molecular autopsy.84,165-167 Using such samples requires
appropriate consent from family, unless ordered by the
coroner. It should be recognized that success varies
depending on the storage method, but attempts to gather
useful DNA may be worthwhile even from suboptimal
sources. Future extraction methods may improve the
yield so continued storage is advisable.
3. Symptoms such as seizures thought to be suspicious for
epilepsy during life may in fact be attributable to a cardiac
channelopathy when further investigation is done. Other
neurological findings such as developmental delay hold
significance for diagnoses such as CPVT. Thus, meticu-
lous recording of neurological events during life may
lead to a diagnosis in SUD.70,146,147,161,162,168,169
4. Recordings from emergency services continuous ECG
monitoring or from interrogation of AEDs, when avail-
able, may provide clues to the etiology of SUD. However,
it should be acknowledged that a finding of ventricular
fibrillation is often due to this rhythm being a final com-
mon rhythm in arrhythmic death, regardless of the initial
rhythm causing hemodynamic collapse. Nevertheless, at
points such as reinitiation of arrhythmia and glimpses of
normal rhythm in between arrhythmia may suggest a spe-
cific diagnosis.158,170
5. The memory function of CIEDs may reveal the initiation
pattern of cardiac arrhythmia and aid in the diagnosis of
SCD. Therefore, if an SUD victim has a CIED implanted
in life, interrogation of this device can provide useful
clues in the diagnosis of SCD.163,171,172
6.3. Investigation of Sudden Death: The
Postmortem Examination and Imaging
The critical components to the investigation of SUD include
examining the circumstances of the death and the autopsy
(Figure 11). Identification of SUD relies on the reporting of
EMS, police, hospitals, and witnesses. Investigation of a
death is determined by the jurisdiction in which the death oc-
curs.14,174,175 Unexpected or unexplained deaths, when the
individual was in apparent good health, should be carried
out by a trained pathologist who has a thorough knowledge
of cardiac pathology.176 Autopsies vary not only by country
but also by individual jurisdictions within countries. The au-
topsy should be comprehensive, examining all organs and
conducted in a systematic and objective method with a focus
on standardized reporting.2,67,177,178 Cases should be referred
to a cardiac pathologist when a cardiac cause is sus-
pected.2,176
Imaging includes X-rays and photography. Photography
is useful in providing documentation of syndromic features
and highlighting individual organ pathology. Postmortem
CT andmagnetic resonance imaging (MRI) have been shown
to be useful179 but are not universally available. Noncardiac
causes should be looked for including infection, thromboem-
bolism, tumors, intracerebral lesions, respiratory disease, and
abdominal causes such as ruptured abdominal aneurysm.
Body mass index should be recorded along with waist
circumference.
Ancillary testing should be performed including microbi-
ology/cultures for infectious disease, metabolic screening
(particularly in younger children), toxicology, vitreous
testing for biochemistry, genetic testing (see Sections 6.4
and 6.5), and other testing as indicated by the autopsy find-
ings. Taking a sample for toxicology is recommended in all
sudden unexpected deaths.180
Samples for genetic testing should be saved at the time of
autopsy from every sudden death case.2,181 Ideally, two of
the following three should be saved: a small piece of fresh
frozen heart, a small piece of fresh frozen spleen/liver/
thymus, and EDTA blood. If RNAlater (ThermoFisher Sci-
entific, Waltham, MA, USA) or similar reagent to preserve
DNA at room temperature is available, fresh tissue can be
transported in this to the referral genetic center without
need for freezing.
The heart should be examined thoroughly67 and at least 7–
10 samples taken for histology. Cardiovascular disease is the
leading cause of sudden death in the young and is divided
into two major groups: morphologically positive (eg,
congenital heart disease, coronary artery disease, and cardio-
myopathy) and morphologically normal hearts. Combined
with negative toxicology, those with morphologically normal
hearts have been labeled as having “autopsy-negative sudden
unexplained death” or “sudden arrhythmic death (syndrome)
or SAD(S).”182 Samples should always be taken, even from a
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macroscopically normal heart, as histology may reveal
inflammation and cardiomyopathies. Always consider sud-
den unexpected death in epilepsy (SUDEP) and sudden death
in alcohol misuse (SUDAM)183 where clinical history and
circumstances are important. Pathologists and clinicians
should not overinterpret findings in the heart at autopsy
such as nonsignificant coronary artery disease, etc.184
Synopsis
A comprehensive autopsy is an essential part of the inves-
tigation of SUD and should include collection and storage of
tissue suitable for genetic analysis. When the autopsy sug-
gests a possible genetic cause, or no cause and the heart is
normal, referral to a multidisciplinary team for further inves-
tigation is indicated (see Section 3).
Recommendation-Specific Supportive Text
1. SUD should have an autopsy done by a trained patholo-
gist.174-176 Studies have shown that autopsies performed
by pathologists who have a thorough knowledge of
cardiac pathology have a superior diagnostic yield.174-176
In cases where autopsy is not possible (eg, for religious
reasons), a full body MRI or CT scan is recommended.179
2. Samples should be taken for infection and toxicology.
Histological sampling of all important organs especially
the heart (from multiple sites) is essential even when
macroscopically normal.174,175
3. Blood or tissue suitable forDNA extraction and postmortem
genetic testing should be obtained at all autopsies.176
Following the initial investigation,DNAshould be extracted
and banked if genetic disease is suspected or if the cause re-
mains unknown.2,176 Ideally, lack of cost coverage should
not be a reason not to comply with these recommendations.
4. Frozen myocardial tissue may be useful for subsequent
RNA analysis or expression studies of aberrant pro-
teins.2,67
5. Cause of death should be discussed in a multidisciplinary
meeting (see Section 3) and provided by a pathologist to
the medical examiner/coroner. The findings and follow-
up recommendations should be communicated to the
family.178,190,191
6. Finding of an abnormal or normal heart is important for
family screening and directs much of the subsequent
investigation (see Sections 6.4 and 6.5).
7. Autopsy phenotype should be established at a multidisci-
plinary meeting of pathologist, medical examiner, cardiol-
ogist, and clinical geneticist.
6.4. Investigation of Sudden Death: Genetic
Evaluation Where the Phenotype Is Known
Genetic evaluation may be appropriate following SCD in two
scenarios: most commonly, where the deceased individual is
the proband with no prior medical history, or alternatively the
deceased is part of a family where diagnosis is established but
he/she has not yet undergone genetic evaluation. Initially,
pathological examination should be performed by an experi-
enced pathologist to ensure that all cardiac and extracardiac
features relevant to the potential diagnosis are recognized
(see Section 6.3).
In caseswhere the deceased is the proband and a postmortem
diagnosis is established, identification of a pathological variant
may facilitate genetic testing in the wider family evaluation. Ge-
netic testing of DNA from the deceased proband may be per-
formed directly after autopsy or deferred until first-degree
family members have been clinically evaluated (Figure 12). As
part of familial evaluation, a three-generation pedigree (at amin-
imum) performed by a practitioner knowledgeable in the ge-
netics of cardiovascular disease (eg, a genetic counselor or
specialist nurse) is mandatory and should cover all potentially
relevant cardiac and extracardiac features within the family
(see Section 6.1). Genetic testing of deceased individuals may
Recommendations for investigation of sudden death: the postmortem examination and imaging
COR LOE Recommendations References
1 B-NR 1. An autopsy is strongly recommended in individuals with an SUD. 14,25,37,175-177
1 B-NR 2. Autopsies for SUD should be comprehensive, including photography, imaging, toxicology,
gross examination of all organs, and detailed examination of the brain, heart, and thorax,
with histology being essential.
14,175-177,180
1 B-NR 3. EDTA blood and/or one type of fresh tissue (heart, liver, spleen, skeletal muscle) should be
saved at autopsy for SUD and banked at 220C or 280C for potential genetic analysis; two
sources are ideal, if possible.
25,70,166,185
2b C-LD 4. Storing frozen myocardial tissue may be considered at autopsy for SUD, as it may aid in
assessing the significance of future genetic findings.
186,187
1 C-EO 5. Findings of an autopsy for SUD should be communicated to the family in a timely fashion in
accordance with local legal requirements.
1 B-NR 6. Cases with likely cardiac causes for SUD should be referred to a pathologist with expertise in
cardiac disease, as thefinding of an abnormal or normal heart is important for family screening.
176,177,184
1 C-LD 7. When an autopsy for SUD reveals a possible genetic cause, or the heart is normal, then
referral for clinical and genetic investigation of the family is recommended.
80,81,143,188,189
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not be covered by health insurance in certain countries; in this
instance, using a clinically affected familymember as the testing
probandwith confirmatory testing in thedeceasedmaybeamore
feasible strategy. Clinical and genetic testing in the proband and
multiple familymemberswill define segregationof the identified
genetic variant(s), adding to the validity of the genetic findings.
The yield of genetic testing in cases where a diagnosis of cardio-
myopathy is established postmortem is significantly greater than
where structural changes are uncertain.192
In cases where no other family members are clinically
affected and the deceased proband is an apparently
isolated case, genetic testing can be used as evaluation
of the single definitely affected individual within the fam-
ily. Families should be counseled about the expected ben-
efits and potential outcomes of genetic investigations prior
to testing. If identified variants are considered likely path-
ogenic or pathogenic, cascade testing across the family
can be considered to identify at-risk individuals with no
current clinical features.
In cases where the deceased is part of a family with a prior
diagnosis of cardiovascular disease and known pathological
variant, confirmatory genetic testing may be performed.
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Figure 11 Investigation of sudden unexplained death: the postmortem examination and imaging. Colors correspond to the Class of Recommendation in
Table 1.
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Synopsis
A postmortem diagnosis following SCD significantly fa-
cilitates further clinical evaluation of family members and
may provide an explanation for the family as to the underly-
ing etiology. Genetic testing targeted toward the clinical
diagnosis and phenotype is an important component of the
overall evaluation of both the proband and family and pro-
vides additional support to the clinical diagnosis. Further in-
vestigations can be performed as clinically indicated. In cases
where no other individuals within the family are clinically
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Figure 12 Clinical and genetic evaluation after sudden death where a phenotype is known. Colors correspond to the Class of Recommendation in Table 1. *See
Section 8.2.
Recommendations for investigation of sudden death: genetic evaluation where the phenotype is known
COR LOE Recommendations References
1 B-NR 1. For SCD where the phenotype is suspected to be heritable, genetic testing is
recommended to attempt to elucidate the genetic basis and to facilitate the identification
of first-degree family members at risk for developing the same disease (cascade testing).
25,80-82,84,85,143
1 C-LD 2. Genetic testing in the deceased proband with SCD and known phenotype should include
only genes with robust evidence of gene–disease association.
192
1 B-NR 3. In first-degree relatives of a proband with SCD from a suspected heritable cause,
phenotype-guided clinical screening is recommended and, where a genetic diagnosis
is available, cascade genetic testing should be offered.
25,80-82,84,85,143,189,193
1 B-NR 4. In families affected by SCD who have undergone genetic testing, periodic re-evaluation
of the genetic test results is recommended.
115,194-201
1 C-LD 5. A genetic diagnosis made in a relative of a proband with SCD should be considered
together with the clinical findings.
70,143,189
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affected, identification of a definitively pathogenic variant in
the proband facilitates cascade genetic testing in family mem-
bers.
Recommendation-Specific Supportive Text
1. Genetic testing in the decedent proband is recommended
to support the clinical diagnosis and facilitate cascade ge-
netic testing within the family.10,11 The yield of genetic
testing is significantly higher when associated with a spe-
cific postmortem diagnosis.84,192
2. If a cardiac phenotype has been identified in the deceased
proband, genetic testing should be targeted toward that
specific phenotype to maximize the chances of a clinically
actionable result and minimize the risk of ambiguous sec-
ondary findings. Targeted panels for cardiomyopathy,
channelopathies, familial thoracic aortic aneurysm, and
familial hyperlipidemia are the preferred option. Howev-
er, given the limited availability of proband DNA and po-
tential financial implications, broader genetic testing
including whole exome and genome with selective report-
ing based on the phenotype may be considered. Robust
evidence for gene–disease association is currently prob-
ably only available in the Clinical Genome Resource
(ClinGen) expert panels for long QT syndrome, Brugada
syndrome, hypertrophic cardiomyopathy, arrhythmo-
genic cardiomyopathy.195,196,202 Wider panels and
whole-exome sequencing/whole-genome sequencing
share the potential disadvantage of a high burden of vari-
ants of uncertain/unknown significance, but in experi-
enced hands (ie, expert centers), this will not lead to
unintended follow-up.203
3. Clinical evaluation for family members of a proband with
an evident or likely phenotype can be targeted based on
that phenotype, although due to varied expressivity and
overlap syndromes should be sufficiently broad to provide
a comprehensive cardiovascular evaluation. If a patho-
genic or likely pathogenic variant has been identified in
the deceased proband in a gene consistent with the clinical
diagnosis, genetic counseling and testing should be
offered to family members.25,80-82,84,85,143,189,193 Cascade
testing for likely pathogenic variants should be done at
the discretion of an experienced provider after
reviewing the data. In cases with limited supporting data
from the family, a more conservative approach may be
appropriate.
4. Serial re-evaluation of variants should be performed based
on new phenotype data in the family pedigree, or new data
regarding both specific variants and whole genes, the
pathogenicity of which may have been up- or downgraded
based on contemporaneous evidence.115,194-196,204 Re-
sponsibility for re-evaluation is unclear, but the re-
evaluation is best carried out in a center of expertise.
5. Genetic variants identified in deceased probands and sub-
sequently in family members should be correlated with
clinical findings to determine segregation patterns within
the family.
6.5. Investigation of Sudden Death: Genetic
Evaluation Where the Phenotype Is Unknown
SCD may occur in an individual without any prior medical
history or medical data. As indicated above, a three-
generation pedigree including examination of all potentially
relevant cardiac and extracardiac features within the family
should be performed by a cardiologist experienced in genetic
heart disease or clinical geneticist experienced in cardiology
in an effort to optimize the identification of subtle clinical fea-
tures before defining the cause of death as unknown. Specific
triggers (eg, competitive athlete, emotional or physical stress,
drug use, swimming, acoustic triggers, seizure) leading to the
SCD event may help focus clinical and genetic investigation.
Collection of blood and/or suitable tissue for molecular au-
topsy/postmortem genetic testing is recommended in all vic-
tims of SUD.2,10 Local protocols are recommended to ensure
proper handling and extended storage of biosamples, as well
as processes and consent allowing for contact of families for
genetic testing in the future.
Family members of sudden death victims where the
phenotype remains unknown should be instructed to request
re-evaluation of the index event in case of future develop-
ments in the family. Clinical signs or symptoms in first-
degree family members leading to a suspected phenotype
of a sudden death victim may occur over many years and
sometimes skip generations, so an unknown phenotype
might prompt more extensive questioning of older family
members.
In an SCD case where the phenotype remains unknown af-
ter expert evaluation, re-evaluation of family members to
assess for new information that may impact diagnosis should
be performed periodically, although the yield is low.205 We
suggest every 3 to 5 years, but shorter intervals should be
considered if there is more than one SCD event in the family.
Periodic re-evaluation should be stopped for individuals after
age 45 years, unless the decedent died in this age range or
new findings emerge.
Three scenarios may trigger arrhythmia syndrome–
focused genetic evaluation of SCD even if the phenotype re-
mains unknown: 1) documented arrhythmic death suggestive
of an arrhythmia syndrome; 2) specific triggers associated
with familial arrhythmia syndromes; 3) young age (,40
years) (Figure 13).
Families should be counseled about the expected benefits
and potential outcomes of genetic investigations prior to
testing. When genotyping is performed, the identification
of a genetic variant as causal remains challenging and re-
quires reassessing the correct classification or potential re-
classification periodically. With rapidly advancing
genotyping technologies and the availability of large gene
panels, the identification of genetic variants of uncertain/un-
known significance becomes more frequent. Medical uncer-
tainty in general elicits a variety of responses from patients.
It is important to consider patients’ responses to the ambig-
uous nature of genetic testing. Medical professionals
ordering genetic testing should be prepared for the possibility
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of their patients’ misinterpretation of such results. Pre-test
counseling should include a discussion of the possibility of
a variant of uncertain significance and what it would mean
for the patient’s care and its potential psychosocial impacts.
When a variant of uncertain significance is found, post-test
counseling should include additional education and a discus-
sion of the variant’s implications and medical management
recommendations based on the results. If identified variants
are considered likely pathogenic or pathogenic, cascade
testing across the family should be offered to identify at-
risk individuals with no current clinical features. Cascade
testing should not be performed with variants of uncertain
significance; however, careful investigation within a multi-
disciplinary team (including genetic counseling) may allow
eventual reclassification of the variant so that it may then
be used for cascade testing (see Sections 3 and 4).
Synopsis
Collection and storage of blood and/or suitable tissue for
postmortem genetic testing is recommended in all victims
of SUD. In a large number of cases, the phenotype underlying
SCD remains unknown despite comprehensive evaluation of
the victim and their family. In SCD cases where the pheno-
type is determined as unknown after expert evaluation, re-
evaluation should be performed periodically to assess for
new information that may impact diagnosis. While
hypothesis-free genetic testing is not indicated in cases of
SCD where the phenotype remains unknown, arrhythmia
syndrome–focused genetic evaluation of SCD is advised if
1) an arrhythmic death is documented suggestive of an in-
herited arrhythmia syndrome, 2) specific triggers associated
with familial arrhythmia preceded the SCD, and/or 3) SCD
occurred at young age.
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Figure 13 Investigation of sudden death: genetic evaluation where the phenotype is unknown. Colors correspond to the Class of Recommendation in Table 1.
SCD 5 sudden cardiac death.
Recommendations for investigation of sudden death: genetic evaluation where the phenotype is unknown
COR LOE Recommendations References
1 B-NR 1. In an SUD case at a young age where the phenotype remains
unknown after expert evaluation, re-evaluation of first-degree
relatives to assess for new information that may achieve
diagnosis should be performed every 3 to 5 years (shorter
intervals should be considered if there is more than one SCD
event in the family) until at least age 45 years.
25,70,80,85,205,206
1 B-NR 2. In an SUD case where the phenotype is unknown, arrhythmia
syndrome–focused genetic testing is recommended if 1)
documented arrhythmic death is suggestive of an arrhythmia
syndrome, and 2) SCD is preceded by specific triggers associated
with familial arrhythmia syndromes.
25,70,80,84,85,185,205-208
2a B-NR 3. In an SUD case occurring in a patient younger than 40 years
where the phenotype is unknown, arrhythmia syndrome–
focused genetic testing can be useful.
25,70,80,84,85,205,206,208,209
3: No Benefit B-NR 4. In an SUD case where the phenotype is unknown, hypothesis-
free genetic testing using exome or genome sequencing is not
indicated in routine patient care, as this may lead to
misinterpretation of genetic variants (specifically variants of
uncertain significance).
210,211
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Recommendation-Specific Supportive Text
1. Genetic diseases may express with reduced penetrance.
Hence, a negative clinical screening does not exclude
the (silent) presence of a genetic disorder. It is, therefore,
reasonable to suggest repeated screening with a time inter-
val between 3 to 5 years until at least age 45 years. Studies
demonstrating the yield of clinical screening after the sud-
den death of a close relative usually report only the result
of the first screening.25,70,80,85,205,206 Responsibility for
the repeated (infrequent) screening lies in the hands of
the individual, but the local team should make sure that
he/she is appropriately informed.
2. In an SCD case where the phenotype is unknown,
arrhythmia syndrome–focused genetic testing of the
proband should be considered if 1) documented
arrhythmic death (such as torsades de pointes arrhyth-
mias leading to ventricular fibrillation) is suggestive
of an arrhythmia syndrome, and/or 2) SCD is preceded
by specific triggers (eg, competitive athlete, emotional
or physical stress, swimming, drug use, acoustic trig-
gers, seizure) associated with familial arrhythmia
syndromes.10,25,70,80,85,205,206,212
Collection and storage of blood and/or suitable tissue for
postmortem genetic testing is recommended in all victims
of SUD irrespective of an identified phenotype at the time
of death. Long-term storage of biosamples of SCD victims
is recommended in expert centers to allow for genetic
testing if indicated at present or in the
future.10,25,70,80,85,205,206,212
3. In an SCD case where the phenotype is unknown,
arrhythmia syndrome–focused genetic testing of the pro-
band can be considered if SCD occurred at young age.
Testing for cardiomyopathy genes (such as LMNA) has
been studied and can increase the diagnostic rate, although
it should be recognized that the yield is
lower.10,25,70,80,85,205,206,212
4. Hypothesis-free genetic testing is not indicated in cases of
SCD where the phenotype remains unknown. Genetic
testing using any range from large unfocused gene panels
to whole-exome or whole-genome sequencing in the
absence of a clinical phenotype or diagnosis may be
considered in the context of a scientific effort but is not
recommended for routine patient care and coun-
seling.213,214 The aim of discouraging hypothesis-free
testing in clinical settings is to reduce the misinterpreta-
tion of genetic variants and their causality, specifically,
variants of uncertain significance. A specific problem in
this field is the nonuniformity in calling variants across
different laboratories.215
Figure 14 summarizes the recommendations from Sec-
tion 6.
Section 7 Investigation of Sudden Cardiac Arrest
Survivors
7.1. Investigation of Sudden Cardiac Arrest
Survivors: History—Personal and Family
When an individual has been resuscitated after SCA, the
clinician must try to define the likely underlying cause,
similar to that discussed in Section 6.1 focused on SCD.
This should include information on age, sex, past medical
history, recent symptoms, activity or emotional status at the
time of SCA (eg, sleeping, exercising, or emotion), time of
onset (eg, morning or night), and environment (eg, public
or private location), exposure to medicinal or recreational
drugs (particularly those that block potassium or sodium
channels) or alcohol, and a detailed family history of three
generations at least.
To focus the history taking, one must consider the differ-
ential diagnosis of SCA, which is similar to that discussed in
Section 6.1. If the SCA was observed, a description of the
event by the observer can add useful information. All records
of the primary event, including initial rhythm recordings and
details of the resuscitation, should be collected in addition to
any prior ECGs and imaging studies. A family history of
heart disease, syncope, or sudden death may point to a ge-
netic cause. A study by Waddell-Smith et al.77 showed that
while inpatient cardiology teams identified a familial condi-
tion in only about 8% of cases, nurses trained in taking a fam-
ily history detected a familial condition in 32% of cases.
Thus, although most patients with SCAwill be in a nonspeci-
alty environment at first, ideally specially trained members of
the cardiology and genetic counselor team with experience in
genetic heart disorders should be utilized to elicit relevant de-
tails of the family history. Practical educational assistance
can be found at https://www.primarycaregenetics.org.
Synopsis
Observational studies have demonstrated that the cause of
SCA can be determined in a substantial proportion of pa-
tients. Historical features, especially age, coronary risk fac-
tors, symptoms, activity at the time of SCA, exposure to
drugs, and family history frequently provide important clues
to the diagnosis and point the way to further investigation.
Recommendations for investigation of SCA survivors: personal and family history
COR LOE Recommendations References
1 B-NR 1. In the investigation of an SCA survivor, detailed personal and three-generation family history
should be taken with the assistance of a multidisciplinary team, including witness accounts.
77
1 B-NR 2. All possible details surrounding an SCA event should be sought, including patient’s
recollection, witness accounts, and medical records.
216-220
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Recommendation-Specific Supportive Text
1. In a study of 37 patients with history of SCD, cardiomy-
opathy, or ventricular tachycardia, a family history ob-
tained by specially trained personnel was far more likely
to elicit a history of inherited cardiac disease than one ob-
tained by an inpatient cardiac team.77
2. A detailed history is a crucial component of diagnosing the
cause of SCA. Studies utilizing a comprehensive, system-
atic approach including history, physical examination,
ECGs (eg, 12-lead ECG, treadmill, 24-hour Holter,
signal-averaged ECG, if needed), cardiac imaging (eg, cor-
onary angiography, echocardiogram, CMR, CT), provoca-
tive testing, electrophysiological study, cardiac biopsy, and
genetic testing have shown that a diagnosis can be estab-
lished in a substantial proportionof survivors ofSCA.216-219
7.2. Investigation of Sudden Cardiac Arrest
Survivors: Examination
The next step in cardiac evaluation of SCA survivors is phys-
ical examination. The main purpose is to identify signs of
syndromic and nonsyndromic diseases that can be associated
with SCA. For example, obesity and/or the presence of xan-
thomata may indicate an increased likelihood of premature
coronary atherosclerosis.221,222 Syndromic features that
may be relevant to genetic disorders include woolly hair
and palmoplantar keratoderma (arrhythmogenic right ven-
tricular cardiomyopathy),140 joint contractures (Emery-Drei-
fuss muscular dystrophy),223 muscle weakness and atrophy
(lamin A/C and desmin cardiomyopathies, Triadin knockout
syndrome),224 micrognathia, syndactyly, clinodactyly (An-
dersen-Tawil and Timothy syndromes),224 chest and limb de-
formities, and tall stature (Marfan syndrome).225,226
Fever, hypothermia, dehydration, and signs of drug abuse
may be detected on physical examination, although these
signs may be confounded by neurological impairment after
cardiac arrest. These factors can trigger life-threatening
arrhythmia in genetic heart disease. For example, fever has
been associated with malignant arrhythmias in 6% of patients
with cardiac arrest and Brugada syndrome.136
Cardiac murmurs can raise the suspicion of left ventricular
outflow tract obstruction, mitral mid-systolic click (valve
prolapse) with or without regurgitation, and Ebstein anom-
aly. Signs of pulmonary edema and hepatosplenomegaly
can be detected in patients with severe systolic myocardial
dysfunction. Importantly, examination findings may be
affected by the SCA event and evolve during a hospital
stay, requiring repeated physical examination to determine
whether findings are related to the cause of SCA or the effect
of SCA.
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Figure 14 Investigation of sudden death. Colors correspond to the Class of Recommendation in Table 1. AED 5 automated external defibrillator; CIED 5
cardiovascular implantable electronic device; ECG 5 electrocardiogram; SCD 5 sudden cardiac death.
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Synopsis
There are no data describing the usefulness of physical ex-
amination in resuscitated SCD. However, it is a first basic
step in the diagnostic process that will focus subsequent com-
plementary investigations.
Recommendation-Specific Supportive Text
1. Protocols for clinics investigating SCA survivors support
the use of physical examination as the first step of clinical
overview.10,216,227
7.3. Investigation of Sudden Cardiac Arrest
Survivors: Baseline Investigations
In most emergency settings, a patient resuscitated from cardiac
arrest inwhommyocardial infarction is suspectedwill have un-
dergone a coronary reperfusion strategy to treat acute occlu-
sion. It is critical to obtain blood tests (cardiac enzymes,
inflammatory markers, glucose, serum electrolytes, and white
blood cell count) and pertinent toxicological analysis at presen-
tation. The latter may include testing for drugs of abuse such as
ethanol, opiates, and stimulants, as well as levels of prescribed
medication that may prolong QT interval/QRS duration or
cause respiratory depression.228 While assisting in the acute
management of a resuscitated patient, these results will also
help to differentiate acute myocardial injury as a cause of car-
diac arrest (eg, ischemiawithout clear evidence of coronary oc-
clusion or myocarditis) and pick up other reversible causes
such as drug overdose, electrolyte imbalance, or endocrine
and metabolic disorders. Retention and storage of suitable
blood samples on patient arrival in the emergency department
will allow subsequent diagnostic evaluation including DNA
extraction and analysis in a patient who dies prior to diagnosis
or for later clinical and family review. In some cases, this may
be the only opportunity to obtain genetic material for analysis.
In an OHCA, the use of AEDs is ever more widespread and
increases survival.229 Sensitivity for the diagnosis of cardiac
rhythm at the time of arrest is about 99%.230 Therefore, routine
inspection of data from AED recordings may improve the
quality of diagnosis (see Section 6.2). The underlying rhythm
of cardiac arrest may provide information on the arrhythmo-
genic mechanism, assist in diagnosis, and eventually indicate
any misdiagnosis of rhythm.231 Any ECG tracings from emer-
gency services, as well as recordings from interrogation of
CIEDs or wearables can also contribute to diagnosis.163
The 12-lead ECG in sinus rhythm or during arrhythmia
recurrence is fundamental to the diagnostic investigation
and should be repeated daily during recovery.216 It may sup-
port diagnoses of primary electrical disorders, pre-excitation,
and heart muscle diseases. However, abnormalities of cardiac
conduction and repolarization may result from myocardial
injury during the cardiac arrest and patients undergoing
post-arrest hypothermia protocols may have transient ECG
changes including QT prolongation and J point elevation
that should be interpreted with caution. Information about
electrolyte levels, drug prescription, and body temperature
should be added to the ECG to prevent misinterpretation of
such ECG abnormalities. A high precordial lead ECG is an
inexpensive tool to increase detection of Brugada syndrome
pattern.184,232-235
In addition to standard ECG, a signal-averaged ECG may
demonstrate late potentials. Two or more abnormalities in the
absence of a prolonged QRS duration (110 ms) on the stan-
dard ECG is a minor diagnostic criterion for arrhythmogenic
cardiomyopathy and suggests ventricular depolarization ab-
normality.4
Continuous heart rhythm monitoring is recommended dur-
ing hospitalization due to the transient nature of some arrhyth-
mias. Recording the onset (including pause-dependent or
tachycardia-associated initiation) and late and short-coupled
ventricular ectopics as triggers for torsade de pointes, polymor-
phic ventricular tachycardia, or ventricular fibrillation will
elucidate cardiac arrest mechanism and likely diagnosis.236
Evidence of dynamic ST elevation associated with chest
pain may also indicate likelihood of coronary vasospasm.216
Echocardiography is the screening tool of choice for struc-
tural heart disease, although early myocardial dysfunction
may be present after cardiac arrest and, if present early, the
test should be repeated later during the patient’s convales-
cence. CMR allows detection of inflammatory diseases,
such as myocarditis and sarcoidosis, through recognition of
subepicardial edema. Identification of an inflammatory etiol-
ogy is important, as it may be self-limiting or treatable. If
sarcoidosis is suspected, then positron emission
tomography–CT scanning may be indicated.237 The presence
of subendocardial edema would suggest ischemic injury.238
Late gadolinium enhancement indicates chronic fibrosis,
permitting detection of a cardiomyopathic etiology, and can
also contribute to the diagnosis of mitral valve prolapse asso-
ciated with a risk of SCD.239,240 Coronary imaging (at any
age) will be important to exclude coronary artery disease
not investigated at presentation as an emergency and ensure
that an anomalous coronary circulation or coronary dissec-
tion is not missed.241 This may be by cardiac catheterization
or by CT coronary angiography.242 Coronary angiography
will only be required in select pediatric and young survivors.
Patients in whom the cause of their SCA remains undiag-
nosed may require periodic re-evaluation of the above inves-
tigations, as features may develop later that point to a cause of
their SCA (similar to Section 6.5, Recommendation 1).
Recommendation for investigation of SCA survivors: examination
COR LOE Recommendation References
1 B-NR 1. Detailed physical examination is recommended after resuscitation from SCA. 136,140,222,224,225
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Synopsis
Systematic clinical testing is paramount in SCA survivors.
This includes blood testing, toxicology, ECG, signal-
averaged ECG, high precordial lead ECG, continuous ECG
monitoring, echocardiography, and coronary imaging. If
the diagnosis remains elusive and cardiac arrest is deemed
unexplained, then CMR is important to identify subtle forms
of cardiomyopathy or acquired structural disease.
Recommendation-Specific Supportive Text
1. The usefulness of blood testing and toxicology is by
consensus, and a diagnostic role is unquestionable.2,10,228
Viral studies may be useful, but no systematic evidence is
available as yet.249 A potential role for biomarkers specific
for one of the arrhythmia syndromes is anticipated.250,251
2. Results of a forensic study indicate the value of postmortem
CIED interrogation to define the cause and timing of death
more accurately and to detect potential CIED-related safety
issues. CIED interrogation in unexplained deaths clarified
the manner of death in 60.8% of the cases including cardiac
and nonarrhythmic death and device concerns.163
3. Sensitivity for the diagnosis of cardiac rhythm via AED at
the time of arrest is about 99%.230 However, the AED
seldom catches the initial rhythm of cardiac arrest and
therefore may not contribute to the etiology of SCA.
4. Primary electrical disorders and specific cardiomyopathies
may be detected by conventional ECG.2,10,216,252 ECG
findings in the immediate aftermath of a cardiac arrest,
other than ST-segment elevation indicative of an acute cor-
onary syndrome, may, however, have poor diagnostic ac-
curacy.253,254 These could be caused by abnormal
repolarization following electrical cardioversion,255 meta-
bolic and electrolyte abnormalities, or even subarachnoid
hemorrhage.256 Therapeutic hypothermia may lead to
misleading ECG changes such as prolongation in PR,
QRS and QT intervals, and J point elevation.257,258 Inter-
pretation of ECGs obtained immediately after resuscita-
tion/defibrillation should be performed with great caution.
5. Although there are no data describing directly the value of
high precordial lead ECGs in SCD survivors, there is
ample evidence of an increased yield of the type 1 Bru-
gada ECG pattern.189
6. Cardiac monitoring during short-term follow-up demon-
strates an arrhythmogenic mechanism of SCD in some
registries.216,236,246
7. Signal-averaged ECG is part of the Task Force Criteria for
arrhythmogenic right ventricular cardiomyopathy.4
Signal-averaged ECG has been proposed as useful in
other conditions (ie, Brugada syndrome), although sys-
tematic evaluation has not been performed.
8. Echocardiography is a valuable screening tool for detec-
tion of arrhythmogenic cardiomyopathy and other struc-
tural abnormalities useful in elucidating the cause of
SCA.85 Patients with functional abnormalities on initial
echocardiogram should have this test repeated after recov-
ery, to allow for the effects of the SCA itself and drugs
used around the time of the arrest to wear off.
9. and 10. The utility of CMR has been evaluated in a se-
ries of studies involving survivors of unexplained arrest
and has repeatedly been shown to provide significant in-
cremental diagnostic value. A study of 137 individuals
with unexplained aborted cardiac arrest found that CMR
provided a diagnosis or identified an arrhythmic substrate
Recommendations for investigation of SCA survivors: baseline investigations
COR LOE Recommendations References
1 B-NR 1. Blood samples for electrolytes, toxicology, and EDTA blood stored for future genetic testing are
recommended for all SCA survivors on admission to hospital.
228
1 B-NR 2. Retrieval of recordings from CIEDs and wearable monitors is recommended for all SCA survivors. 243-245
2b C-LD 3. Retrieval of recordings from AEDs and ambulance services may be useful for all SCA survivors. 158,170
1 B-NR 4. Recording of 12-lead ECGs during sinus rhythm and, if possible, during arrhythmia, is recommended
for all SCA survivors.
85,150,153,
216,246
1 C-LD 5. A high precordial lead ECG is recommended in all undiagnosed SCA survivors to increase detection of
a type 1 Brugada ECG pattern.
189,232-235
1 C-LD 6. Continuous ECG monitoring is recommended for all SCA survivors during the initial hospital stay. 85,216,246
2b C-LD 7. A signal-averaged ECG may be useful in SCA survivors to aid in the diagnosis of arrhythmogenic
cardiomyopathy.
247
1 B-NR 8. Echocardiography is recommended for evaluation of cardiac structure and function in all SCA
survivors.
85,216
1 B-NR 9. CMR with late gadolinium enhancement is recommended for evaluation of acute or chronic
myocardial disease in SCA survivors without a clear underlying cause.
238,248
2a B-NR 10. CMR can be useful for evaluation of acute or chronic myocardial disease in SCA survivors, when the
etiology is primary electrical or there is evidence for acute cardiac ischemia.
238,248
1 B-NR 11. Coronary imaging is recommended in all adult SCA survivors, to exclude coronary artery disease,
dissection, or anomalies not considered fully at first presentation, and in select younger cases.
241
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in 76% of individuals, including an infarct pattern sugges-
tive of occult myocardial infarction in 44%. Notably, the
presence of late gadolinium enhancement, reflective of
myocardial fibrosis, was associated with a 6.7 hazard ratio
(p, 0.001) of recurrent arrhythmic events on multivariate
analysis.248 The presence of subendocardial edema would
suggest ischemic injury even when initial coronary imag-
ing excludes significant obstruction. Coronary vasospasm
and dissection might be misdiagnosed, and coronary re-
evaluation may then be reconsidered.238 The frequency
of occult infarcts is not insignificant,248 although the
risk of SCD in patients with myocardial infarction and
nonobstructive coronary arteries is low.259 For Recom-
mendation 10, primary electrical disease is not referring
to an established diagnosis of long QT syndrome or
CPVT, where MRI is unlikely to be of use.
11. Coronary artery disease is the leading cause of SCD in
adults and might be treatable. Furthermore, coronary
dissection and anomalies may also be relevant in this
age group as well as in younger patients.
7.4. Investigation of Sudden Cardiac Arrest
Survivors: Provocative Testing
Once a cardiac arrest survivor has undergone initial thorough
baseline evaluation, most overt acquired or genetic etiologies
will have been diagnosed. However, concealed disorders
may be uncovered by provocative maneuvers such as lying
to standing ECGs, exercise ECG testing, epinephrine chal-
lenge, sodium channel blocker challenge, or ergonovine
and acetylcholine testing. Some may even be employed in
a resuscitated cardiac arrest survivor who is unlikely to sur-
vive due to neurological injury.
Exercise testing may uncover ventricular arrhythmia rele-
vant to the cause of cardiac arrest. For example, evidence of
monomorphic ventricular tachycardia arising from the right
ventricle is part of Task Force Criteria for diagnosis of arrhyth-
mogenic right ventricular cardiomyopathy (arrhythmogenic
cardiomyopathy).260-262 Exercise may also uncover
concealed epsilon waves or even a type 1 Brugada ECG
pattern.263,264 The generation of bidirectional ventricular ec-
topyor tachycardia and/or polymorphic ventricular tachycardia
in the absence of ischemia, structural disease, or digoxin
toxicity is typical of CPVT265 and has been evaluated in the
Cardiac Arrest Survivors with Preserved Ejection Fraction
Registry (CASPER) protocol.216 Abnormal dynamics of repo-
larization in response to challenges may also inform the likeli-
hood of underlying long QT syndrome. To this end, maximum
QT prolongation (QT stretch) and T-wave morphology
changes during lying to standing and then return to baseline
heart rate (QT stunning) may be useful markers, although
they are less specific in children.266-268 These discriminate
well in genotyped families and may add to diagnostic utility,
but evaluation in unexplained cardiac arrest survivors has not
been undertaken.269 The recovery phase of exercise may also
reveal readily measurable QT prolongation and T-wave abnor-
malities and has been validated in families with long QT
syndrome for prediction of genotype270,271 and in cardiac arrest
survivors216 such that a QTc .480 ms at 4 min of recovery
forms part of the long QT syndrome risk score.272
Epinephrine challenge with ECG monitoring has been
advocated as an alternative to exercise testing for the diag-
nosis of long QT syndrome and CPVT, particularly where
the patient is unable to exercise. In long QT syndrome, QT
prolongation and secondary T-wave changes have been
able to discriminate LQT1 and LQT2 patients from unaf-
fected family members even though they have normal base-
line QTc intervals.273,274 The test has been assessed in
unexplained cardiac arrest survivors and has suggested a
low specificity for long QT syndrome.275 The finding would
be unlikely to provide a secure diagnosis in isolation and was
proposed as useful in association with exercise testing and
genetic testing. Indeed, in normal subjects, pharmacological
sympathetic stimulation does produce significant prolonga-
tion of QTc.276 Epinephrine testing has also shown some
diagnostic utility for CPVT in cardiac arrest survivors by
inducing ventricular ectopic activity, bidirectional couplets,
and ventricular tachycardia.275 However, there is uncertainty
as to the ideal cutoff for epinephrine-induced arrhythmia, and
the diagnostic sensitivity compared to exercise testing in
CPVT families is low.277 Isoproterenol challenge for the
diagnosis of arrhythmogenic right ventricular cardiomyopa-
thy has also been advocated but has not been tested by other
groups or in the unexplained cardiac arrest survivor without
overt phenotype.278
Sodium channel blocker challenge (ajmaline, procaina-
mide, flecainide, and pilsicainide) has been used extensively
for investigating the possibility of Brugada syndrome in car-
diac arrest survivors, although these are mainly reported in
series of patients with a strong suspicion of Brugada syn-
drome279-281 rather than in unexplained cardiac arrest
survivors.282 The use of leads V1 and V2 in the second and
third intercostal space or high right precordial ECG leads dur-
ing provocation increases the diagnostic yield.233,283 In the
CASPER registry, there was a yield from procainamide chal-
lenge,284 although this may underestimate the true burden, as
different sodium channel blockers have different potencies
for inducing the type 1 Brugada ECG pattern. For example,
ajmaline is associated with an odds ratio of 8 for inducing
the type 1 Brugada ECG pattern compared with procaina-
mide285 and a 4% yield in a small group of “healthy” con-
trols.286 Furthermore, while recent consensus guidelines
would give a definite diagnosis to a cardiac arrest survivor
with a type 2 or 3 pattern converting to a type 1, the implica-
tion of a drug-induced type 1 pattern without a baseline type 2
or 3 is not addressed.152 Yet cardiac arrest survivors from
CASPER without a type 2 or 3 pattern had positive procaina-
mide challenges.284 Other tests such as the full stomach test
have been proposed but have not been taken up in general.287
Different approaches for provocation of an underlying
repolarization abnormality have been employed including
drug challenge with quinidine and sotalol and mental stress
tests.288-291 These may offer utility in the future but have
not been tested in the cardiac arrest survivor.
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Coronary vasospasm, while a recognized cause of cardiac
arrest, may not be picked up clinically at presentation.292
Ergonovine or acetylcholine challenge has been proposed
as a Class 1 indication by recent guidelines293 and was em-
ployed selectively in the CASPER experience.216 Hyperven-
tilation has also been used as a diagnostic test.294 Recent
experience from the Paris Sudden Death Expertise Center in-
vestigators suggests that pharmacological challenge is useful
for diagnosis and could be better employed.295 Nonetheless,
there are few centers with extensive experience in the use of
the test, and there is a possibility of false-positive findings in
the cardiac arrest survivor population.
Adenosine challenge has been used to unmask pre-
excitation that may otherwise be missed.296,297 In the
absence of other causes, it will indicate the need for elec-
trophysiological study to evaluate the risk of the accessory
pathway (rapidity of antegrade conduction) followed by
ablation therapy. However, electrophysiological study is
not routinely included in the workup of unexplained car-
diac arrest.8 Indeed, previous consensus guidelines pro-
posed a Class 3 indication when assessing a suspected
primary electrical disorder.8 It does not add additional
diagnostic or prognostic value unless there is evidence to
indicate otherwise. For example, pre-excited atrial fibrilla-
tion, bundle branch re-entrant ventricular tachycardia, and
rapid supraventricular tachycardias that degenerate into
ventricular fibrillation have all previously been described
as culprits requiring an invasive approach to diagnosis
and curative ablation therapy.298,299 Electroanatomic
voltage mapping of the right ventricle is a discretionary
tool that may be considered to detect evidence of subclin-
ical arrhythmogenic right ventricular cardiomyopathy.300
More recently, extensive endocardial and epicardial map-
ping of unexplained cardiac arrest cases has been em-
ployed to identify cases with either Purkinje triggers and/
or subtle depolarization abnormalities that may be suitable
for ablation therapy.301
Synopsis
Concealed Brugada syndrome, long QT syndrome,
CPVT, arrhythmogenic cardiomyopathy, pre-excitation,
and coronary vasospasm may be uncovered by provocative
maneuvers in the cardiac arrest survivor whose cause of car-
diac arrest remains unknown after baseline clinical, ECG,
and imaging investigations. Exercise ECG testing and so-
dium channel blocker challenge appear to offer most poten-
tial utility, whereas lying to standing ECGs; epinephrine,
isoproterenol, and adenosine challenge; and hyperventila-
tion, ergonovine, and acetylcholine testing may be consid-
ered in specific patients. Electrophysiological study and
electroanatomic mapping may be useful to provide patient-
Recommendations for investigation of SCA survivors: provocative testing
COR LOE Recommendations References
1 B-NR 1. Exercise testing is recommended in all undiagnosed SCA survivors to induce arrhythmias that
may support the diagnoses of arrhythmogenic cardiomyopathy and CPVT and to evaluate
dynamic depolarization or repolarization features that may support the diagnoses of Brugada
syndrome, arrhythmogenic cardiomyopathy, and long QT syndrome.
216,220,263-265,
270,271,302,303
2a B-NR 2. Lying to standing ECGs can be useful in SCA survivors for the diagnosis of long QT syndrome,
but must be interpreted with caution in children.
266-270
2b B-NR 3. Epinephrine challenge may be considered for the diagnosis of long QT syndrome and CPVT, in
those unable to exercise.
273-275,277,304
1 B-NR 4. Sodium channel blocker challenge with standard and high precordial ECG leads is
recommended for the diagnosis of Brugada syndrome in undiagnosed SCA survivors with
suggestive clinical characteristics, including a type 2 or 3 Brugada ECG pattern.
233,273-275,
277,286
2a B-NR 5. Sodium channel blocker challenge with standard and high precordial ECG leads can be useful
for the diagnosis of Brugada syndrome in SCA survivors where no other disorder has been
identified.
233,279-282
2b B-NR 6. Ergonovine, acetylcholine, or hyperventilation testing when performed in experienced
centers may be considered for the diagnosis of coronary vasospasm as the cause of SCA in a
survivor where no other disorder has been identified.
216,294,295
2b C-LD 7. Adenosine challenge may be useful for the unmasking of ventricular pre-excitation and
therefore the diagnosis of rapidly conducted atrial arrhythmia as the likely cause of SCA in a
survivor where no other disorder has been identified.
297
2a C-LD 8. An electrophysiological study can be considered if bundle branch re-entrant ventricular
tachycardia, pre-excited atrial fibrillation, or supraventricular tachycardia are suspected in
an SCA survivor.
298,299
2b C-LD 9. Electroanatomic right ventricular voltage mapping may be considered for detection of
subclinical arrhythmogenic cardiomyopathy in an SCA survivor where no other disorder has
been identified.
300
2b C-LD 10. An electrophysiological study may be considered in an SCA survivor where no other disorder
has been identified to evaluate potential underlying substrate.
301
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specific insights into the mechanism of cardiac arrest and
offer therapeutic options but should be avoided in the routine
investigation of channelopathy. However, data in general are
limited to case reports or case series, some with validation co-
horts, and there are no randomized studies.
Recommendation-Specific Supportive Text
1. Exercise testing is a versatile, straightforward, and readily
available test thatmay yield diagnoses due to the arrhythmic
challenge or effects on depolarization and repolarization. As
such, it should be a standard part of the investigative
armamentarium.216,220,263-265,270-272,302,303
2. Lying to standing ECGs may offer some insights into the
likelihood of long QT syndrome, but in isolation a posi-
tive result may not fulfill diagnostic criteria and therefore
may only complement the evaluation.266-270
3. Similarly, epinephrine challenge has low specificity for
long QT syndrome and may be insensitive for CPVT. In
isolation, a positive result may not fulfill diagnostic
criteria and therefore may only complement the evalua-
tion.273-275,277,304 There are risks to this test, both in
inducing ventricular arrhythmia and in false diagnosis.
4. Sodium channel blocker testing has a clear role to play in
evaluating the cardiac arrest survivor, although the impli-
cation of a positive result in patients with or without a high
prior likelihood of Brugada syndrome is unclear, eg, male
vs. female, cardiac arrest during sleep vs. exercise, type 2
or 3 ECG pattern vs. no Brugada pattern at baseline. This
reflects the lack of a gold standard for the diagnosis of
Brugada syndrome, and therefore the utility of sodium
channel blocker challenge in patients without a clear prior
likelihood of Brugada syndrome is less certain and merits
a lower utility in the evaluation cascade.233,273-275,277,286
Furthermore, sodium channel blocking agents differ in
their sensitivity and specificity for inducing ECG changes
and availability varies worldwide (see Section 7.4
text).285
5. See 4.233,279-282
6. The utility of ergonovine or acetylcholine challenge or hy-
perventilation testing in all cardiac arrest survivors is un-
clear, as there are no studies of systematic testing in all
cardiac arrest survivors. In particular, the specificity of
the test is unknown, especially in the cardiac arrest survi-
vor population. It can, however, lead to diagnoses when
employed in a protocol and therefore should be consid-
ered as part of the armamentarium until more evidence
is available.216,293-295
7. Adenosine challenge has not been tested systematically in
cardiac arrest survivors, but there are limited data suggest-
ing that it will uncover concealed pre-excitation that may
cause cardiac arrest in the setting of rapidly conducted
pre-excited atrial tachyarrhythmias.296,297
8. There are limited case series describing the use of electro-
physiological study in diagnosis and treatment of pre-
excited atrial arrhythmias and bundle branch re-entrant
ventricular tachycardia.298,299
9. Studies of endocardial mapping report a higher sensitivity
for detection of arrhythmogenic cardiomyopathy, but this
has not been explored in SCA survivors.300 Sensitivity
and specificity are unknown, particularly in patients
where no other tests are abnormal.
10. Extensive endocardial and epicardial mapping of unex-
plained cardiac arrest cases has been employed to iden-
tify cases with either Purkinje triggers and/or subtle
depolarization abnormalities that may be suitable for
ablation therapy.301
7.5. Investigation of Sudden Cardiac Arrest
Survivors: Genetic Evaluation
Although most SCA survivors will have an indication for an
implantable defibrillator for secondary prevention of a car-
diac arrest,6 genetic evaluation may influence final diagnosis,
treatment recommendations, and family screening
(Figure 15). In some cases, genetic evaluation may enable
therapy specific to the disease mechanism. Recent technolog-
ical advances in genetic evaluations, establishment of refer-
ence databases of genetic variants, systematic annotation of
causal genes,305 and standardization of variant interpreta-
tion306 have enabled efficient and comprehensive genetic
assessment. However, the pace of genetic discovery and
variant interpretation is evolving rapidly, creating a complex
landscape surrounding genetic evaluation of SCA survivors.
The decision to pursue genetic evaluation is an individu-
alized one in which the patient, with proper (clinical and ge-
netic) counseling, must weigh the benefits, limitations, and
personal and familial implications. The genetic basis of
SCA and most individual conditions that predispose to
SCA remain incompletely understood. As such, caution is
advised when interpreting negative genetic test results or
when examining genes with low likelihood of causing
SCA. Prior clinical practice guidelines have specifically ad-
dressed the diagnostic considerations regarding specific ge-
netic cardiovascular conditions.4,10,307 The ClinGen
represents a systematic effort to enumerate causal genes
and variation related to human disease, including SCA-
related conditions.305 Previous reports have been developed
for Brugada syndrome,195 long QT syndrome,196 and hyper-
trophic cardiomyopathy.202
The yield of genetic testing varies substantially by condi-
tion.188 Variant interpretation may differ by laboratory215
despite recent efforts to standardize variant interpretation.306
Given the rapid changes in available technology to evaluate
the genome, complexities in variant interpretation, and nu-
ances in the ethical and legal framework surrounding genetic
testing in some settings,66,115,215,308-310 it is recommended
that SCA survivors undergoing genetic assessment have
evaluations performed at centers with multidisciplinary
experience in counseling, variant interpretation, and
management of genetic heart disease (see Section 3). For
SCA survivors who have undergone genetic testing, an offer
of periodic re-evaluation of the genetic test results is advo-
cated (similar to Section 6.4, Recommendation 4).
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Synopsis
SCA can be caused by diverse etiologies, some of which
maybepredominantly or partially influencedbygenetic predis-
position. Whereas a thorough clinical evaluation leads to a
diagnosis of the cause of SCA for most individuals, the cause
of SCA may remain uncertain in others.216 In some cases, ge-
netic evaluation of SCA survivors can confirm a molecular eti-
ology that predisposed to the SCA event, support the diagnosis
of a specific phenotype, influence management, and facilitate
screening in familymembers at risk via cascade genetic testing.
Recommendation-Specific Supportive Text
1. Genetic testing, after appropriate genetic counseling and
informed consent, may facilitate identification of a molec-
ular cause of SCA by identifying pathogenic variants in
genes associated with specific phenotypes and fulfilling
formal disease-based diagnostic criteria.4,10 Examples of
scenarios in which discovery of a genetic cause of SCA
may influence management recommendations include
administration of beta blockade for patients with long
QT syndrome,311 sodium channel inhibition in long QT
syndrome type 3,312-314 flecainide administration for
patients with CPVT,315,331 or exercise restriction recom-
mendations in patients with arrhythmogenic cardiomyop-
athy.316,317 Genetic evaluation may also influence family
screening by facilitating cascade genetic testing and clin-
ical surveillance in relatives at greatest risk for disease.
2. and 3. Genetic tests have variable yield and may result in
discovery of variants of uncertain clinical significance,
which can be frequent and challenging to interpret. Using
genetic tests that comprise well-established genes related
to a suspected or diagnosed genetic phenotype ismost likely
to result in discovery of disease-causing variants in an indi-
vidual or family, while minimizing the probability of
discovering a variant of uncertain clinical significance. In
contrast, genetic tests with more comprehensive genomic
coveragemay lead tomoderately increased diagnostic yield
but at the expense of increased rates of discovery of variants
of uncertain clinical significance.84,308 Nevertheless, given
a rapidly evolving understanding of the molecular causes
of specific phenotypes and increased yield of broader ge-
netic assessment,82,84,246,323,324 tests that include broader
coverage may be considered in select circumstances, such
as when a heritable phenotype is being mapped within a
family or assessment for de novovariation is sought through
sequencing of multiple family members. The latter exam-
ples would only be pertinent when it becomes apparent
that a familial trait is likely or there has been exome
sequencing in a trio of confirmed parents and the index case.
4. Genetic evaluation appears to be highest for individuals
with a phenotype consistent with a genetic cause84,323,324
and is lower among SCA survivors without a clearly identi-
fiable genetic phenotype.82,84,246,323-326 Nevertheless,
individuals with an idiopathic cause of SCA may
eventually develop a diagnosis of a genetic etiology
during long-term follow-up.327 Genetic testing can identify
variants during the concealed phase of a genetic disease
such as arrhythmogenic cardiomyopathy,328 or in individ-
uals with conditions otherwise regarded as nongenetic
such as in drug-induced long QT syndrome.329 As such, a
low but non-negligible yield for genetic testing appears to
be present among individuals with idiopathic SCA.
5. In individuals with a well-established nongenetic cause of
SCA, the routine use of genetic evaluation is not recom-
mended owing to the potential for discovery of variants
of uncertain significance and misdiagnosis.
Figure 16 summarizes the recommendations from
Section 7.
Section 8 Investigation of the Family
8.1. Background
The sudden death of a young, apparently healthy individual
raises many questions for family members. Apart from
mourning and the question “could we have done something
to avoid this,” a very relevant question is whether family
members could be affected as well. Roles for health care pro-
viders include providing psychological support for the fam-
ily, identifying a cause for the sudden death, and
Recommendations for genetic evaluation of SCA survivors
COR LOE Recommendations References
1 B-NR 1. Genetic evaluation of SCA survivors is recommended for those with a diagnosed or
suspected genetic cardiac disease phenotype when the results are likely to influence
diagnosis, management, or family screening.
84,311-322
1 B-NR 2. When genetic evaluation is performed in an SCA survivor with a suspected or diagnosed
genetic cardiac disease phenotype, it is recommended that evaluations include only
genes where there is robust gene–disease association.
84,308
2b B-NR 3. When genetic evaluation is performed in an SCA survivor with a suspected or diagnosed
genetic cardiac disease phenotype, assessment of genes or genomic regions that are not
known to be causally related may be considered in select circumstances.
84
2b B-NR 4. Genetic evaluation of SCA survivors without a distinct genetic cardiac disease phenotype
may be considered in select circumstances.
82,84,209,246,323-330
3: No Benefit C-EO 5. Genetic testing in SCA survivors with a well-established nongenetic cause of SCA is not
recommended.
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understanding the implications for family members (see Sec-
tions 4 and 5). For this chapter, it is especially relevant that
families need support to organize clinical and genetic testing
for family members and sometimes postmortem genetic
testing of the deceased.2,101,332
Currently, many cases and even familial forms of unex-
plained cardiac disease remain insufficiently investigated.333
When clinical symptoms indicate that a cardiomyopathy or
arrhythmia may have contributed to the death, further steps
are needed to specify the diagnosis. If blood or tissue of the
deceased is available, DNA testing can be done for a range
of arrhythmia syndromes and cardiomyopathies, nowadays
often using gene panels. Without a specific diagnosis in the
deceased, clinical investigation of the first-degree relatives
(parents, siblings, and children) can identify a person with
similar symptoms or signs, although sometimes mild. This
relative of the deceased can be the proband for DNA testing
and thus provide the key to a diagnosis for the family.
Efforts are needed to increase the proportion of postmor-
tem examinations (either forensic or medical autopsy) to
clarify whether or not an underlying cause can be suspected
or proven. The postmortem result should be communicated to
the family as per local protocols. Without a postmortem diag-
nosis, efforts are needed to evaluate eventual clinical symp-
toms of the parents and other first-degree family
members.80,81,143,144,334 This is outlined in Section 6. If
DNA of the deceased person can be used for testing, or a rela-
tive who has similar symptoms can be tested, a monogenic
form of cardiomyopathy or arrhythmia may be recognized
that may also be present in family members. Typically,
first-degree relatives are at 50% risk of carrying the same
pathogenic mutation, since many of these conditions follow
an autosomal dominant pattern of inheritance.
Depending on whether or not autopsy has been performed,
whether DNA is available, whether a relative is already diag-
nosed with a cardiogenetic condition, and whether symptoms
were noticed during life, there are different situations
possible: 1) sudden death, with clinical observations or
DNA testing suggesting a specific diagnosis, and 2) sudden
death, with no cause identified. The first situation will be dis-
cussed in Section 8.2, the second in Section 8.3 (Figure 17).
8.2. Investigation of the Family: Cause
Identified—Cascade Testing, Clinical and Genetic
Investigations
In cascade testing, after the postmortem diagnosis in an index
patient by a DNA test, an invitation can be sent to parents,
brothers and sisters, and children.335 If any of the relatives is
also diagnosed with the condition, a next circle of first-
degree relatives is invited. If one of the first-degree relatives
is not available (either deceased or not wanting to participate),
second-degree relatives are invited, for instance, children of a
deceased sibling. This systematic approach is very effective in
autosomal dominant conditions, since first-degree relatives are
at 50% a priori risk to carry the same pathogenic mutation and
second-degree relatives at 25% risk. For minors, the age at
which treatment starts determines the age before which
DNA testing is advised. This may differ between countries
and conditions. DNA testing of minors is not advised if the
result would have no consequences in childhood.
Presymptomatic DNA testing makes it possible to organize
preventive measures, such as regular cardiological follow-up,
use ofmedication (eg, beta blockers), lifestyle advice (eg, avoid
intensive sports), implantable cardioverter-defibrillators, or
reproductive planning.80,193,336-342 Presymptomatic DNA
testing also puts an end to uncertainty and fear for those
family members who test negative.339 For them, follow-up in-
vestigations are no longer indicated.
In studies describing cascade screening, often the partici-
pation of relatives is limited.343-348 This implies that many
persons carrying pathogenic variants remain undiagnosed
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Figure 15 Investigation of sudden cardiac arrest (SCA) survivors: genetic evaluation. Colors correspond to the Class of Recommendation in Table 1.
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and are at continued risk of sudden death. Increasingly,
geneticists and other stakeholders plea for an active
approach to cascade testing for conditions where
interventions are available.349-351 Stakeholders agree on the
importance of early diagnosis and informing the
family.2,340,352 Barriers to cascade screening include out-
of-pocket expenses for the patient, limited resources for in-
forming relatives, and privacy regulations.339,351,353,354 To
benefit from predictive, personalized, and preventive medi-
cine, the roles and responsibilities of stakeholders in genetic
testing as a preventive strategy need to be carefully aligned.
If clinical signs and symptoms suggest an inherited condi-
tion but no DNA test has been performed or no pathogenic
variant has been identified, then history, examination, and
clinical investigations of first-degree relatives are required
to identify those at risk for SCD.
Synopsis
Apostmortemdiagnosis in a victim of SCD implies the pos-
sibility of avoiding sudden death in relatives. This requires an
active approach to inform parents, siblings, and children of
the index case andoffer clinical evaluationandpotential genetic
testing. Amultidisciplinary service should support all elements
of recognizing an inherited cardiac disorder in a victim (pathol-
ogist), identifying pathogenic mutations (geneticist), clinical
evaluation and surveillance of carriers of the mutation (cardiol-
ogist), and supporting the patients and relatives (psychologist).
Recommendation-Specific Supportive Text
1. Since undiagnosed cardiogenetic conditions can be life-
threatening and since interventions are available to reduce
the risk of sudden death, first-degree relatives who are at
50% risk of carrying the pathogenic variant need to be
informed about the possibilities of clinical investigations
and genetic testing.70,84,346,355,356 Second-degree relatives
whose intervening first-degree relative refuses genetic
testing (or is not available) should be offered testing due
to a 25% risk.
2. Patients often can inform their relatives at risk, but medi-
cal professionals increasingly feel ethically responsible to
support this process.349,350,357 Supplying a letter for the
patient to share with relatives is advised. Occasionally,
directly contacting relatives may be possible in some
jurisdictions. Studies have shown that there is substantial
room for improvement of the uptake of family screening.
Barriers include reluctance to consent to postmortem in-
vestigations, lack of information, and lack of funding
for the services. While the services needed should involve
many disciplines (pathologist, cardiologist, geneticist),
the systematic approaching of family members fits the
specialty of clinical genetics well. To achieve a high up-
take, a systematic approach is needed.
3. The identification of at-risk individuals leads to the ques-
tion of whether all require active treatment. Prospective
clinical studies are needed to answer this question. To bal-
ance pros and cons for survival and for quality of life on
treatment, long-term follow-up of persons following the
suggested surveillance and interventions is needed. Preci-
sion prevention advice should build on this evidence.
4. In families with genetically affected individuals (with or
without clinical findings), detailed prenatal counseling
and guidance regarding inheritance patterns, variant pene-
trance, and risk should be offered, and other options
including preimplantation genetic diagnosis should be
explored.336-338
8.3. Investigation of the Family: Cause Not
Identified—Clinical and Genetic Investigations
Sudden death in the young is always a tragedy for those lost and
the remaining family. When the cause of sudden death is not
identified, either because there was no postmortem examina-
tion or because the autopsy was negative, significant anxiety
in the family focuses on two major questions: why did the sub-
ject die suddenly and what risks apply to the remaining family
members?An autopsy is typically requested, and in some juris-
dictions mandated, but may not be completed because of cul-
tural, family, or logistical limitations. When a postmortem
examination establishes a cause of death, diagnosis transitions
from SUD to death attributed to autopsy-related findings (see
Section 8.2). When no underlying anatomic or toxicologic
cause of death is identified with forensic autopsy, the descrip-
tion of the death goes from SUD to sudden arrhythmic death
(syndrome)/SAD(S), since death is attributed to a presumed
arrhythmia, or autopsy-negative SCD. In the case of
Recommendations for investigation of the family: cause identified—cascade testing, clinical and genetic investigations
COR LOE Recommendations References
1 C-LD 1. If a pathogenic or likely pathogenic variant that fits with the phenotype has been identified in
an SCD proband, first-degree relatives should be offered DNA testing, with ongoing clinical
evaluation for those testing positive.
70,84,346,355,356
1 C-LD 2. SCA survivors should be encouraged to provide information to at-risk relatives, and health
care providers should support and document this process.
350,357
1 C-LD 3. The effectiveness of treatment strategies and interventions in relatives with pathogenic or
likely pathogenic variants of genes related to SCD should be investigated in clinical trials.
333,358
1 B-NR 4. In families affected by SCA, reproductive genetic counseling should be offered to discuss risks
and options for future or current pregnancies.
336-338
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nonspecific findings, follow-up of families should be similar to
that with a negative autopsy.184,359
When sudden death is classified as SAD or autopsy-
negative SCD (ie, SUD), the differential diagnosis includes
a breadth of inherited conditions that are predominantly ion
channelopathies, with latent cardiomyopathy a consideration
based on subtle autopsy findings. Causes include long QT
syndrome, CPVT, short QT syndrome, Brugada syndrome,
and arrhythmogenic cardiomyopathy. Careful review by a
trained cardiac pathologist is recommended to ensure that as-
signed causes or absent causes are accurate (see Section 6.3).2
Recent studies have shown that a genetic evaluation of the
deceased subject’s DNA associated with a clinical evaluation
of first-degree relatives of the deceased subject retrospec-
tively identified the cause of death in 20–40% of
cases.70,80,81,143,144,189,334 In this situation, the identification
of the cause of sudden death provides an explanation to the
family and facilitates further cascade screening. In a second
step, it will enable prevention measures in the family to limit
the risk of a second death.
Synopsis
Screening of first-degree relatives of the SCD victim is
informed by findings from the forensic investigation. Though
the yield of genetic testing is relatively low, results should be
applied to all first-degree relatives in conjunction with clin-
ical assessment. In the absence of genetic results, screening
tests should include a medical history, standard and high pre-
cordial lead ECG, 24-hour ambulatory monitoring, echocar-
diography, and exercise test, with select use of
pharmacological provocation and advanced imaging.
Recommendation-Specific Supportive Text
1. Although autopsy is recommended, family screening after
suddendeath in youngpatients is effective evenwhenan au-
topsy is not conducted. Broad screening of first-degree rel-
atives with systematic testing is warranted.80,81,143,144,334
Combining molecular autopsy with clinical evaluation in
surviving families increases diagnostic yield.70 The value
of surveillance testing after negative evaluation is uncertain,
though commonly undertaken until age 45 years (range:
40–50 years), with decreasing frequency with age.85 The
context of SCD, the family history, and existing findings
should inform the potential merits of ongoing surveillance,
including frequency and duration. The age at which and
from which onward surveillance is warranted depends on
the (suspected) underlying condition.
2. When decedent genetic testing detects a pathogenic or
likely pathogenic variant, the result enables identification
of all family members at risk of SCD.80,81,143,144,334 It is
important to combine genetic and clinical evaluation,
especially when the pathogenicity of the detected variant
is uncertain, to evaluate the correlation between the ge-
netic finding and clinical diagnosis for each family.83 If
DNA is not available from the decedent and no clinical
phenotype is present in the family, genetic testing of fam-
ily members should be strongly discouraged.
3. Several studies have demonstrated that family screening
should include at least a medical history, standard and
high precordial lead ECG (to improve the detection of
the Brugada syndrome), echocardiography, exercise
test,80,81,143,144,334 and Holter monitoring on a case-by-
case basis.
4. CMR and 24-hour ambulatory monitoring of family mem-
bers can inform diagnosis.4,5
5. and 6. A careful assessment of the circumstances of sud-
den death may point to a specific diagnosis. Sudden death
in a young or middle-aged male occurring during a febrile
illness or sleep suggests the diagnosis of Brugada syn-
drome, whereas sudden death occurring in a subject
Recommendations for investigation of the family: cause not identified—clinical and genetic investigations
COR LOE Recommendations References
1 B-NR 1. Family screening should be advised in first-degree relatives of SUD subjects with a negative
autopsy (or with no autopsy) when the decedent’s age is,45 years (and in all patients with a
clear phenotype regardless of age).
80,81,143,144,334
1 B-NR 2. Family screening should include genetic testing and clinical evaluation when genetic testing
of a proband with SUD detects a pathogenic or likely pathogenic variant.
70,80,81,84,143,144,
189,334
2a B-NR 3. It is reasonable to take a medical history and perform physical examination, standard and
high precordial lead ECG, echocardiography, and exercise testing in first-degree relatives of
SUD subjects.
80,81,143,144,334
2b C-LD 4. Depending on the results of other investigations (ECGs, echocardiography, and exercise
testing), it may be reasonable to perform ambulatory cardiac rhythm monitoring and CMR in
first-degree relatives of SUD subjects.
70,81,143,189,360
2a B-NR 5. It is reasonable to screen select postpubertal family members of SUD subjects with
pharmacological testing including sodium channel blocker when baseline testing or proband
findings increase suspicion of the target diagnosis.
143,189,205,275,288,334
2b B-NR 6. It may be reasonable to screen first-degree relatives of SUD subjects with pharmacological
testing including epinephrine challenge (if exercise testing is impractical) and sodium
channel blockade.
189,205,275,288,334
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during physical activity suggests the diagnosis of long QT
syndrome or CPVT. As Brugada syndromemay bemasked
or intermittent in some patients, sodium channel blocker
challenge may unmask the type 1 pattern and increase the
effectiveness of family screening. It should be recognized
that there is a potential high rate of false positives, as data
on the specificity and sensitivity of the test are not available,
and a positive ECGmay be induced in 4–5%of normal sub-
jects.286,361 In the pediatric age group, a negative test may
convert to a positive test after puberty.362 Long QT syn-
drome may also be unmasked by standing, exercise test,
epinephrine test, or mental stress test.266,269,270,275,288 In
first-degree relatives of young SUD victims with no mani-
fest abnormalities during the initial examination, the risk
of developing manifest inherited cardiac disease or cardiac
events during follow-up is low.205
Section 9 Future Directions
Many of the recommendations in this document seem intu-
itive, obvious, and straightforward; however, much of what
is being recommended within this document is seldom
routinely performed even in well-resourced countries.
Many decedents of SUD never receive an autopsy, and
the evaluation of first-degree relatives of an SUD victim
or an SCA survivor ranges widely from no evaluation to
ordering a multitude of tests that are then repeated regu-
larly and indefinitely. The extensive variability in practice
indicates that developing common sense processes and
multidisciplinary teams remains a considerable challenge
in many areas and guidance is required. Developing these
processes and teams involves leaders challenging many
medico-political barriers that obstruct and delay best
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Figure 16 Investigation of sudden cardiac arrest survivors. Colors correspond to the Class of Recommendation in Table 1. AED 5 automated external defi-
brillator; AF 5 atrial fibrillation; BBR-VT 5 bundle branch re-entry ventricular tachycardia; CIED 5 cardiovascular implantable electronic device; CMR 5
cardiac magnetic resonance imaging; CPVT5 catecholaminergic polymorphic ventricular tachycardia; ECG 5 electrocardiogram; EP 5 electrophysiological;
LQTS 5 long QT syndrome; SCA 5 sudden cardiac arrest; SVT 5 supraventricular tachycardia.
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medical practice. We hope that this document will
empower those who wish to achieve such changes for
the better, including efforts for continuous improvement
of practice. So, assuming the recommendations in this
document are embraced and implemented, what are the
next steps and future directions in this field?
Firstly, unlike cancer statistics and even SCD in the
elderly due to coronary artery disease, the precise prevalence,
epidemiology, and etiologies of either SUD or SCA in the
young remain obscure in most countries. Only if these condi-
tions become a notifiable event will the true scale and scope
ever be captured.
Secondly, communities, states/provinces, and countries
must advocate for and expect that a true comprehensive au-
topsy, including postmortem genetic testing (ie, molecular
autopsy), occurs whenever an SUD occurs in a young person.
The current dismal rate of autopsy must be reversed. Only
when this becomes the standard of care will the true epidemi-
ology/etiology of SCD be determined.
Thirdly, the basic occurrence and subsequent extent of an
evaluation of the living, whether she/he is an SCA survivor or
the first-degree relative of an SUD victim or an SCA survi-
vor, must become standard of care. After initial cardiological
evaluation (examination, ECGs, stress test, and echocardio-
gram) has been completed, the true contribution of SCA-
predisposing genetic heart disease will be exposed. Further-
more, the composition and contribution of advanced investi-
gations ranging from sodium channel drug provocation
studies, to MRI, to genetic testing requires further study, as
does the recommended interval for a repeat cardiological
evaluation of the first-degree relatives when their first evalu-
ation is either normal or inconclusive.
Finally, when such investigations are commenced, future
studies to minimize the collateral damage from uncertain
clinical findings and genetic “variants of uncertain signifi-
cance” will be needed. While it is recognized that the correct
necropsy diagnosis of the SUD decedent and the correct diag-
nosis of the SCA survivor may give patients and their fam-
ilies some answers and resolution to the event, the
premature and erroneous diagnosis due to excessive confi-
dence in or overinterpretation of clinical or genetic findings
of uncertain significance can cause remarkable harm. If we
are to “first do no harm,” the model of multidisciplinary
teams with the expertise to correctly evaluate all the investi-
gations and potential (mis)diagnoses should be made acces-
sible to all.
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Figure 17 Investigation of the family affected by sudden cardiac arrest and/or sudden unexplained death when cause is identified or not identified. Colors
correspond to the Class of Recommendation in Table 1. CMR5 cardiac magnetic resonance imaging; ECG5 electrocardiogram; SCA5 sudden cardiac arrest;
SCD 5 sudden cardiac death; SUD 5 sudden unexplained death.
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Supplementary Data
Supplementary data (Appendix 3) associated with this article
can be found in the online version at https://doi.org/10.1016/
j.hrthm.2020.10.010.
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viewers. AHA 5 American Heart Association; NIH 5 National Institutes of Health.
50
H
eart
Rhythm
,Vol
-,No
-,
-
2020
P
G
L
5
.6
.0
D
T
D

H
R
T
H
M
8
5
6
2
_p
ro
o
f

2
2
O
cto
b
er
2
0
2
0

3
:1
7
a
m

ce
